Delcath Systems is already past that point.

Delcath is an interventional oncology company focused on cancers that spread to the liver. Its main product, HEPZATO, delivers high-dose chemotherapy directly to the liver while filtering much of the drug out before the blood returns to the rest of the body.

I first came across Delcath in January through another investing Substack I followed at the time. What caught my attention was that this wasn’t just another biotech waiting on a trial result. HEPZATO was already generating revenue, Delcath had cash and no debt, management was buying back shares, and the stock still looked cheap.

That investor later sold around $10 for almost no gain to put the money into other opportunities. I went the other way. I bought my first lot in June and added a little more in early August. Now, with DCTH trading just under $17 after a strong Q2, I’m finally doing some selling of my own, but for a different reason. The business has done what I hoped it would do, and the market has started to recognize it.

I never bought Delcath expecting it to become one of my core compounders. I have other investments for that. This was more of a “pay for the groceries, fix the car and keep the rest of my savings compounding” kind of investment. If a good swing gives me a meaningful return, I’m perfectly happy taking it rather than forcing every winner into a forever holding.

HEPZATO is approved and commercial. Revenue is growing. Gross margins reached 90% last quarter. Delcath has roughly $96 million in cash and investments, essentially no debt, and the existing business is now generating enough cash to help fund trials aimed at much larger cancer markets.

So the question has changed. I’m no longer asking whether Delcath can become a real business. I’m asking how large that business can become, how much of the future is already reflected in the current stock price, and how much I should pay today for indications that might not arrive for years.

After going through the filings, investor deck, earnings call, clinical data and competitive landscape, I still like what I see. The business is stronger than it was when I first bought the stock, but the share price has also moved enough that valuation matters a lot more now.

The rest of the deep dive comes down to four questions: what HEPZATO is worth in the current indication, how much credit the pipeline deserves, what the recent rerating has already priced in, and how I’m handling my own position after the run.

What changed in Q2

Q2 made the commercial story a lot more convincing.

Revenue reached $29.1 million, ahead of expectations, including $27.1 million from HEPZATO. HEPZATO treatment volume grew about 30% year over year and 17% sequentially, while Delcath raised full-year revenue guidance to $104–$108 million.

Gross margin hit 90%, which is the number that really caught my attention. This isn’t a low-margin medical-device business that needs massive scale before the economics start working. Delcath is already producing pharmaceutical-like gross margins, and the approved mUM franchise is now generating enough cash to help fund the attempt to turn HEPZATO into a broader oncology platform.

Management put it plainly on the call: the commercial mUM business is now helping fund development in additional liver-dominant cancers.

_{Source: FinChat/Fiscal.ai. Quarterly revenue and free cash flow, $ millions.}

How HEPZATO works

What finally made HEPZATO click for me was realizing that Delcath isn’t really selling a new chemotherapy drug. Melphalan itself has been around for decades. The innovation is in how they deliver it: isolate the liver, hit it with a much higher local dose, filter the blood, and return it to circulation.

Delcath says the process delivers more than six times the local chemotherapy concentration, can treat both visible tumors and microscopic disease throughout the liver, and its proprietary filtration system removes more than 85% of the chemotherapy from the returning blood.

That whole-liver claim is the important part. TACE and Y90 are established liver-directed alternatives, but Delcath argues they’re less suited to diffuse microscopic disease because they generally target portions of the liver or individual tumors. HEPZATO is designed to treat the liver as an organ rather than chase tumors one at a time. The same complexity that differentiates HEPZATO also makes adoption harder. Patients need a referral to trained treatment centers, the procedure requires specialized interventional-radiology teams, general anesthesia and REMS certification. The FDA label also carries boxed warnings for serious peri-procedural complications and myelosuppression, so it doesn’t come without friction.

The commercial machine is starting to work

Delcath ended Q2 with 31 active centers and expects approximately 37 by year-end. Roughly 80% of its active centers are NCI Comprehensive Cancer Centers, and the company is already present at 41% of all 58 such centers and approximately half of NCCN member institutions. Recent additions include MD Anderson, Mayo Clinic Scottsdale, Columbia and UT Southwestern. These are the kind of centers that receive complex oncology referrals, influence standards of care and train other physicians, which matters more to me than the center count.

Delcath says new patient starts are running around 0.5 per active site per month. Because patients generally receive a series of treatments extending across multiple quarters, new starts today create recurring procedure volume later.

Management estimates around 800 U.S. patients per year fit the current HEPZATO label, putting the total addressable market for metastatic uveal melanoma at roughly $500 million. While that figure isn’t a direct sales forecast, it highlights a clear takeaway: a HEPZATO franchise pulling in $100 million annually still has plenty of runway.

The 340B hit is a pricing gap, not a demand problem

One of the cleanest disclosures from the recent earnings call clears up an apparent disconnect: HEPZATO volume grew ~30%, but revenue grew only 21%.

The gap was 340B pricing. Management noted that 340B discounts dragged the realized price per kit down from around $185,000 to $170,000–$173,000, accounting for virtually the entire difference between unit growth and top-line growth.

While that price realization is a headwind, it’s the right kind of problem to have. I’d much rather hold a company absorbing a mix-driven price dip while volume jumps 30% than one hitting 21% top-line growth through price hikes on flat demand. Plus, even with the discount, gross margin still hit 90%.

Reimbursement has also become less of a barrier since launch. HEPZATO now has its own permanent billing code, making it easier for hospitals to bill insurers specifically for the drug. It also has Medicare outpatient pass-through reimbursement through March 2027 and additional payment support for certain inpatient cases, reducing some of the financial friction for hospitals using the treatment.

The income statement hides something important…

If you’ve read this far, you already know why Delcath caught my attention. The rest of the deep dive gets into the part that matters most to me as an investor: what the reported numbers really mean, how much dilution I’m modeling, what the clinical data does and doesn’t prove, the competitive risk I think the market may be underestimating, and what I believe DCTH is actually worth.

Paid subscribers can continue below for the full valuation, risk analysis, F.L.O.W. scorecard, and how I’m handling my own position after the run.

Read more

Markets often work the same way. A strong earnings report does not suddenly create a strong business. A major customer announcement does not build the product overnight. A profitable quarter does not produce the years of work that came before it. Those events make the progress visible. Once the progress becomes visible, more investors believe it, uncertainty falls, and the company starts earning a better valuation. The moment people feel safest buying is often the moment the stock is no longer cheap.

The D-BOX lesson

D-BOX has been teaching me this lesson in real time. When I first started studying the company, the product was easier to understand than the business. Moving theater seats make sense. People pay more for a more immersive experience, theaters gain another premium offering, and D-BOX earns money from selling systems and collecting royalties as those systems are used. The harder question was whether an interesting product could become a dependable business.

For years, the numbers were uneven. Theater spending was lumpy, the company was small, and customer concentration mattered. It was unclear whether D-BOX would become something durable or remain a niche entertainment company with occasional strong periods. Then the evidence improved. Revenue moved above C$50 million. Gross margins rose above 50%. Operating income turned positive, cash flow became meaningful, and royalties grew. The active screen base expanded, Cinemark kept adding D-BOX locations, and F1 Arcade opened another commercial path outside traditional theaters.

I still waited for the full fiscal 2026 results before finishing my valuation work. At the time, that felt disciplined because the next report actually mattered. If the earlier improvement faded, D-BOX might have remained a fun product story without dependable earning power behind it. If the numbers held, the company deserved a more serious owner’s earnings analysis. The numbers held. D-BOX reported record revenue, record adjusted EBITDA, record royalties, and a much stronger balance sheet. The stock traded as high as C$1.03 after the report, with volume several times above its recent average. I got the proof I wanted. I also got a higher stock price.

Since then, the stock seems to get another push whenever D-BOX announces a meaningful theater expansion, and that reaction makes more sense once you look beyond the news release. A new installation can create an initial system sale, but it also adds to the installed base from which future royalties may be earned. The hardware expands the footprint, while the recurring revenue can gradually improve the quality of the business. D-BOX has also explained that theater system sales can move around with exhibitor spending, the film slate, box office conditions, and the timing of capital projects. The royalty stream matters more to me because it can make the company less dependent on repeating large hardware sales every quarter. Each new installation does not prove the entire thesis. It proves one small part of it, and over time those pieces can add up to a business the market is willing to value differently.

The market does not give us certainty at the old price

Investors sometimes talk about risk and valuation as though they move independently. We say we want a company to become less risky, but we also hope to buy it at the price available when the risks were much higher. Markets rarely work that way.

A small company may have a product customers like, a large opportunity, early signs of improving margins, a few important customer relationships, and no long record of consistent cash generation. The stock may look inexpensive because several questions remain unanswered: can the company scale, will customers keep buying, will margins hold, can management turn growth into cash, will the company need to issue more shares? Now imagine that the business reports four stronger quarters. It adds customers, expands margins, generates cash, and raises guidance. The investment has become less risky because several ways it could have failed have been removed, and the business has become more valuable. The higher price may simply mean the company has earned more trust. The mistake is believing we can wait until the uncertainty is gone and still get the price that existed when uncertainty was everywhere.

Proof should remove a specific doubt

Not every company announcement deserves a higher valuation. Markets are full of announcements that sound important but do very little to improve the underlying economics. Some partnerships never produce material revenue, pilot programs stall before commercial rollout, and a customer win may be too small to change the economics. Rapid growth can come from discounts that weaken margins, while adjusted profit can hide a business that keeps consuming cash.

When I look at new evidence, I ask what uncertainty it removes and whether it improves the economics or only the story. Can it be repeated? Where should it eventually show up: revenue, margins, cash flow, or ROC? Most important, does it make one of the ways the thesis could fail less likely?

For D-BOX, each new theater installation matters because it gives the company another place to earn royalties over time. As that installed base grows, the revenue mix can become more recurring and the business a little easier to predict. That can justify a higher valuation. An announcement only counts as proof when it changes the economics, not just the story.

What exactly am I waiting for?

There is nothing wrong with waiting for another quarter. Sometimes the next report genuinely matters. The full fiscal year mattered for D-BOX because I wanted to know whether the profit improvement was becoming durable. Even after the strong year, the main question remained: if theatrical system sales cooled, could royalties, screen growth, and cost control still support the owner’s earnings base? In that case, waiting had a purpose.

The trouble starts when “one more quarter” becomes an automatic response. Before waiting, I should be able to say what the next quarter needs to prove. Margins may need to hold after a temporary surge. Customer concentration may need to fall. Recurring revenue may need to become a larger share of sales. Cash flow may need to catch up with reported earnings. Management may need to repeat a strong year without unusual help or heavy dilution. Those are measurable questions.

Sometimes I cannot name the missing evidence. I only know that I do not feel ready. In that situation, I may be waiting for comfort rather than proof. Comfort is understandable. This is real money, and at my age I am not interested in gambling away capital that took decades to build. An ugly chart, an unproven business, or a tiny company with limited trading volume deserves caution. But in martial arts, caution works best when you know what you are reacting to. You do not tense up at every movement. You identify the threat, stay balanced, and respond to what is actually in front of you. Investing should work the same way. The goal is not to eliminate caution. It is to make caution specific.

There are different levels of proof

A company does not move from unproven to proven in one step. The evidence usually builds across five stages:

1. Product proof: customers want the offering

2. Commercial proof: customers pay enough to drive growth

3. Economic proof: growth produces healthy margins and cash

4. Repeatability proof: results hold across multiple periods

5. Capital allocation proof: management reinvests cash productively

Different investors enter at different points. Some are willing to buy when the product has only begun to prove itself. Others need to see commercial traction, healthy cash flow, or several years of repeatable results. None of those approaches is automatically wrong. They accept different levels of risk and pay different prices. Buying earlier can produce a larger return, but it also creates more ways to be wrong. Waiting improves the odds while often leaving less upside. Proof changes the odds. It does not remove the need to think about price.

The starter position sits between guessing and certainty

One reason I have become more comfortable with starter positions is that the choice does not have to be between owning nothing and committing a full position. A starter can make sense when the thesis is promising, the evidence is improving, and important questions remain. The position should be small enough that being wrong is manageable, but large enough that I pay attention.

There is a meaningful difference between watching a company for six months and owning even a small amount for six months. Watching can stay abstract. Ownership changes how carefully I read the quarterly report, what I notice in management commentary, and how honestly I react to volatility. I have written before that a starter position keeps an idea alive without pretending the thesis has already been proven. If the company keeps executing, it can earn more capital. If the evidence weakens, the damage stays limited.

D-BOX may have deserved that treatment earlier. I did not need to know with certainty that fiscal 2026 would be strong. I needed to decide whether the early evidence was good enough for a small position and what the company would have to prove before I added more. In martial arts, you do not always wait until every movement is obvious before you engage. You make controlled contact, test the distance, stay balanced, and adjust as you learn more. You see boxers do this all the time. But Bruce Lee was a master at this. A starter position could have done the same for me here. Instead, I waited until the evidence became much easier to explain. There is no shame in that. Waiting did its job. It protected me from buying too early, but it also kept me out while the business was earning a higher value.

Some proof is already in the price

A company can keep reporting good news while the investment becomes less attractive. More proof raises my confidence in the business, but I still have to weigh that confidence against what the stock price already assumes.

D-BOX looked more attractive around C$0.80 than it did near C$0.95, even though the company was more proven at the higher price. At C$0.95, the level I used in my Part 2 analysis for paid subscribers, the reverse DCF suggested the market was already pricing in roughly 7% to 8% annual owner’s earnings growth. That growth hurdle was reasonable, but the stock was no longer in obvious bargain territory. The business was becoming safer. The valuation was becoming less forgiving. Both can be true at the same time.

So a working thesis does not automatically mean the stock remains a buy. Every new proof point should make me update two questions: how likely is the business to succeed, and how much success does the current price already require? Ignoring the first question can make me miss a real inflection. Ignoring the second can make me overpay for one.

Training before the belt

As I start preparing for September, I know I will not walk into the test feeling certain about every part of it. Preparation has to begin now. The next few months will show me where my balance breaks down, which forms need more attention, and what happens to my technique when I am tired. Each class will give me another piece of evidence. I will not wait until I feel like a black belt before training for the test. I will train along with a couple other students, learn, adjust, and let the work show me what still needs improvement.

Investing can follow the same process. I do not need complete certainty before starting a position. I need enough evidence to justify the risk, a position size that respects what remains unknown, and a clear sense of what the company must prove next. Then I can adjust as the evidence changes. I can add when the business earns more capital, wait when the price gets ahead of the progress, and leave when the evidence starts moving in the wrong direction.

The test in September will not create the skill. It will reveal what the training has produced and where the gaps remain. By the time a business has done the same for investors, it may be easier to trust and more expensive to own.

Proof has value. It is rarely free.

Keep Moving,
TuDi

Disclaimer

The information in this article is provided for informational and educational purposes only.

The information is not intended to be and does not constitute financial advice or any other advice, is general in nature, and is not specific to you. Before using this article’s information to make an investment decision, you should seek the advice of a qualified and registered securities professional and undertake your own due diligence.

None of the information in this article is intended as investment advice, as an offer or solicitation of an offer to buy or sell, or as a recommendation, endorsement, or sponsorship of any security, company, or fund. The author is not responsible for any investment decision made by you. You are responsible for your own investment research and investment decisions.

The share-price move makes the answer look simpler than it is. Acquisition charges are distorting Halozyme’s reported results. The royalty mix is improving faster than the headline numbers show, and the 2029 patent debate is far more complicated than the usual “patent cliff” narrative suggests. The company still carries real risk: product concentration, partner dependence, and an unproven Hypercon platform. What the current price already assumes about the years after 2028 is the most interesting part of this, and it’s where the investment case either holds up or falls apart.

1. What Halozyme Actually Does

Halozyme helps drug companies turn intravenous or difficult subcutaneous medicines into faster and easier injections. ENHANZE uses a recombinant human hyaluronidase enzyme called rHuPH20. The enzyme temporarily opens space under the skin so a much larger dose can be delivered subcutaneously. For patients, this can turn an infusion that takes hours into an injection that takes minutes. For the drug owner, it can protect market share, improve convenience, open new care settings and sometimes create fresh formulation patents around an established franchise.

The business arrangement is the attractive part. A partner such as Johnson & Johnson, Roche or argenx pays upfront licensing fees, development milestones and commercial milestones. Halozyme also sells bulk rHuPH20 and receives royalties that average in the mid-single digits when the partner product reaches the market. The pharmaceutical partner funds most clinical development, regulatory work, manufacturing of the finished drug, sales and marketing. Halozyme earns a percentage of the successful product without carrying the full cost and risk of owning the product itself. The company currently receives royalties from ten commercial ENHANZE products across five Roche products, two Janssen products and one product each from Takeda, argenx and Bristol Myers Squibb.

This structure explains the financial profile. Royalty revenue carries minimal direct cost, so every additional dollar can drop through at a very high margin. Product sales and collaboration revenue are lower quality and more uneven, but they support partner relationships and the future royalty stream. Royalties represented about 62% of 2025 revenue and are expected to become an even larger share as the current products mature.

2. Why the Product Matters

The benefit is easy to understand without a science degree. DARZALEX can be given in roughly three to five minutes rather than through a long infusion, and management says the subcutaneous formulation lowers infusion-related reactions. OCREVUS ZUNOVO can be given twice a year in about ten minutes. PHESGO combines two breast-cancer antibodies in one subcutaneous injection. VYVGART Hytrulo gives patients with autoimmune disease a more flexible treatment option and now has a prefilled syringe for self-administration. These are meaningful changes to the experience of living with a chronic or serious disease.

Commercially, this matters just as much: hospitals have limited infusion-chair capacity, doctors can treat more patients, and a subcutaneous formulation can help a branded drug defend itself as the original intravenous product ages. Once a partner has completed formulation work, clinical studies, regulatory filings and a commercial launch around ENHANZE, changing the delivery technology is expensive and risky. That creates a form of switching cost even though Halozyme does not own the underlying medicine.

The Moat

The moat comes from years of clinical validation, regulatory familiarity, product-specific patents, manufacturing know-how and deep relationships with major drug companies. A competitor can develop another hyaluronidase or formulation technology, but it cannot instantly recreate the approval history and installed base behind ten marketed products.

Halozyme’s business model looks excellent on the surface, but the investment decision turns on several harder questions: how concentrated the royalties really are, what happens after the original ENHANZE patents expire, whether Hypercon deserves any value today, and how much future decline the current stock price already assumes.

The easy part is seeing why Halozyme is an attractive business. The harder part is deciding what the stock is worth after a 50% run. For paid subscribers, I work through the royalty concentration, patent timeline, owner earnings, DCF and reverse DCF, and the exact prices where I would buy, add, or stop adding.

Read more

The chart still looks pretty beaten up. The business, though, does not.

This is not some clean, widely loved compounder where everyone already agrees the story is great and the stock trades at a premium. DLocal still has plenty of baggage: the post-IPO collapse, the short-seller overhang, the emerging-market discount, worries about take rates, and the market’s general skepticism toward fintech.

And to be fair, some of that skepticism makes sense. But after Q1, I think the market may still be spending too much time looking at the scars and not enough time looking at what the business is actually doing.

What is DLocal?

DLocal is a Uruguay-based payments infrastructure business headquartered in Montevideo. It helps large global merchants accept payments, make payouts, and settle transactions across emerging markets through a single API. The value proposition basically comes down to instead of a merchant building local payment connections country by country, DLocal gives them access to local cards, wallets, bank transfers, real-time networks, mobile money, and other local payment methods across more than 60 markets.

• DLocal processed $14.1 billion of TPV in Q1, up 73% year over year. That was the sixth consecutive quarter with TPV growth above 50%.

• Revenue grew 55% year over year to $335.9 million.

• Gross profit grew 40% year over year to $118.7 million.

• Operating profit was $52.8 million as reported, or about $57 million excluding a one-off prior-period tax adjustment.

• Net Revenue Retention remained very strong at 152%.

And despite the messy bottom-line optics from the tax adjustment and elevated first-half OpEx, management kept full-year 2026 guidance unchanged:

• TPV growth: 50–60%

• Gross profit growth: 22.5–27.5%

• Operating profit growth: 27.5–32.5%

Revenue and gross profit are shown in millions. The chart uses actual annual results through 2025 and shows the disconnect between DLocal’s business growth and the stock’s post-IPO reset.

The business has continued to compound, but the stock still reflects a damaged fintech narrative. This is still a high-growth, profitable, cash-generative payments infrastructure business trading with a trust discount.

At first glance, that combination looks hard to ignore. But the real question is whether the trust discount is still deserved. Let’s take a deeper look.

The Market Is Worried About the Right Thing

The main bear argument is take rate which is a fair concern.

Gross profit as a percentage of TPV has been declining. In Q1, gross profit / TPV was roughly 0.84%, down from around 1.05% a year ago and 0.88% in Q4.

If you stop there, the bear case is easy:

• DLocal is growing volume, but earning less on each dollar processed.

• Large merchants are squeezing pricing.

• Competition is increasing.

• The company has to run faster just to stay in place.

That argument sounds reasonable, which is why the stock still does not get much credit for the headline growth. But I think it misses the point. DLocal is not trying to maximize take rate. It is trying to maximize long-term gross profit dollars, merchant share of wallet, and scale across emerging markets.

At the JPM conference, Pedro Arnt, DLocal’s CEO, described declining take rates as “an inherent feature” of what DLocal is trying to build, not simply a flaw in the model.

The better way to think about take rate may be less as something DLocal is trying to “defend” and more as something it is trying to redirect into scale, gross profit dollars, and deeper merchant relationships.

Payments is a scale game. If DLocal can win large global merchants, process more volume across more countries, and then cross-sell new products over time, the absolute economics can improve even while headline take rates compress.

Not “Will take rates fall?” They probably will. The better question is whether TPV growth and gross profit dollar growth can more than offset that compression while OpEx grows slower over time.

So far, the answer is yes: TPV grew 73%, gross profit grew 40%, and operating profit, normalized for the one-off tax item, grew 25%.

The economics are messy, but the business is still clearly scaling.

Gross profit margin has declined as DLocal has scaled with larger global merchants. The bull case is that TPV growth, gross profit dollars, and operating leverage can more than offset that compression.

Why Emerging-Market Payments Are DLocal’s Moat

The reason DLocal exists is simple: emerging-market payments are fragmented, local, and hard to scale. That complexity is not just the problem DLocal solves, it is also the moat.

In developed markets, payments infrastructure is relatively standardized. Cards still dominate, the rails are mature, and a global merchant can usually plug into Stripe, Adyen, or another large provider and get broad coverage across many countries without having to think too much about the local payment stack.

Emerging markets are a very different story. Payment methods are far more fragmented, and winning in these markets often means supporting local wallets, local card schemes, real-time payment networks, bank transfers, mobile money, cash-adjacent methods, local acquiring, local settlement, and country-specific regulatory requirements.

That is why payments become much more strategic in DLocal’s markets. If a global merchant wants to sell into Brazil, Mexico, Nigeria, Kenya, Egypt, Colombia, Vietnam, Peru, South Africa, or the Middle East, payments are not just a back-office function. They become part of the go-to-market strategy because consumers in each market may prefer very different ways to pay.

• DLocal sells one API, covering more than 60 countries and over 1,000 payment methods.

• 38 licenses and authorizations across 26 markets.

• 16 more license applications in process.

• More than 760 enterprise merchants.

This is not a flashy moat. It is built through licenses, local relationships, regulatory know-how, integrations, and years of operating experience in difficult markets.

That may sound boring, but in payments, boring infrastructure can be very valuable. DLocal’s job is to make fragmented emerging-market payments easier for global merchants to use.

Arnt put it simply on the Q1 call: “Those foundations are not easy to replicate and even harder to outperform.”

DLocal’s Merchant Expansion Flywheel

The strongest evidence for DLocal is not just that big merchants sign up. It is what happens after they start using the platform.

Management shared a few examples on the Q1 call that make the model easier to understand.

• One ride-hailing merchant started with DLocal in 2016 and now works with the company across 18 countries, while also expanding into on-demand delivery.

• An internet service provider expanded from 19 countries to 40 in just three years.

• And an e-commerce merchant that joined in 2023 started in only two countries but now operates with DLocal in 21 markets, with BNPL recently going live in Mexico and South Africa.

That is the playbook: land with one use case, expand into more countries, add more payment methods and products, and gradually take more share of wallet.

This is why DLocal’s revenue retention matters. Revenue retention above 140% for four straight quarters suggests the company is not just processing transactions. It is becoming part of how large merchants expand across emerging markets.

Once DLocal is working for a merchant, the easiest path is often to add more countries and products instead of rebuilding local payment infrastructure from scratch in every market. That does not make the business risk-free, but it does create real switching costs.

DLocal’s Diversification Is Reducing Country Risk

DLocal will always have country volatility. That comes with operating across emerging markets.

Argentina can be messy. Brazil can swing with seasonality and funding costs. Egypt can recover one quarter and disappoint the next. FX, capital controls, regulation, tax changes, and local politics will always be part of the story.

The way to manage that risk is diversification. DLocal needs a broader mix of countries, verticals, merchants, and products so no single market can define the whole business.

In Q1, management said growth was broad-based across countries, verticals, merchants, and products. Mexico, Brazil, and Argentina remained important, but they also called out strength in Chile, Nigeria, Colombia, and Vietnam.

Travel grew 38% quarter over quarter, on-demand delivery grew 24%, and Africa and Asia represented about 29% of gross profit, growing 16% sequentially, faster than the company average.

DLocal cannot eliminate volatility in emerging markets, but it can build a more diversified portfolio of markets and verticals so no single geography dominates the story. It is not fully there yet, but it is moving in the right direction.

DLocal’s Q1 Was Messy, But the Core Business Still Looked Strong

The market’s reaction to Q1 made sense at first glance.

Operating expenses were elevated, net income looked messy, free cash flow had working-capital noise, and the company had a prior-period tax adjustment. None of that is what investors want to see from a company still trying to rebuild trust.

But underneath the noise, the quarter was stronger than the headline reaction suggested.

The tax adjustment was $9.7 million, with $4.4 million hitting operating expenses and $5.3 million hitting the tax line. Management said it was non-recurring and does not expect it to repeat in future quarters.

The bigger issue is OpEx.

DLocal spent the past two years investing in product, compliance, regulatory infrastructure, automation, and local teams. Because much of that hiring and investment happened later in 2025, the full cost is showing up more clearly in the first half of 2026.

Management’s message is pretty simple: H1 margins are under pressure, OpEx growth should moderate through the year, and operating leverage should become more visible in H2.

DLocal expects “improving operating leverage in the back half of the year.”

That’s the number one thing I want to see.

The company deserves some benefit of the doubt because the top line remains so strong. But this cannot become a permanent excuse. If operating leverage does not show up in the second half, the market will probably punish the stock again.

DLocal’s UBS Upgrade Shows the Market May Be Warming Up

UBS recently upgraded DLocal to Buy and raised its price target from $16 to $20, which is a small sign that the market may be starting to take the numbers more seriously. Since I started drafting this, DLO has moved into the mid-$15s, which makes the setup a little less obvious than it was a few days ago, but still worth analyzing.

For a long time, DLocal has traded like a company where every good quarter came with an asterisk.

• Strong TPV growth? Yes, but take rates are falling.

• Strong gross profit growth? Yes, but working capital is noisy.

• Strong balance sheet? Yes, but emerging markets are risky.

• Strong revenue retention? Yes, but merchant concentration is still a concern.

But at some point, if the company keeps executing, the burden of proof starts to shift. The question becomes less “Why should we trust this?” and more “What if the business is actually better than the stock suggests?”

That is why the UBS upgrade is worth noting. It suggests some investors may be starting to view DLocal less as a broken fintech and more as a profitable emerging-market payments infrastructure business.

The Russell 2000 addition helps too. It should improve visibility and potentially liquidity, even though it does not change intrinsic value.

The Valuation Still Looks Reasonable

At around $15 per share, DLocal’s valuation does not look stretched for the growth profile. The company is trading around:

• 15x next-twelve-month earnings

• 8–9x next-twelve-month EV/EBITDA

• Under 2x next-twelve-month EV/sales

• Roughly 10–11x trailing free cash flow

That is not expensive for a company guiding to the TPV, gross profit, and operating profit growth outlined above. Using the company’s 2026 operating profit guidance of roughly $281–291 million, the current enterprise value implies something close to 12x forward operating profit.

That seems too cheap if DLocal can execute. But the “if” matters. This is not a no-brainer valuation if take-rate compression gets worse, if OpEx does not normalize, if working capital remains ugly, or if large merchant deployments disappoint.

Capital Allocation Is Becoming More Attractive

DLocal is also not a typical high-growth fintech story that needs outside capital. The company is profitable, carries a strong balance sheet, generates cash, has no meaningful net debt, and is returning capital to shareholders.

The dividend policy is tied to 30% of prior-year free cash flow. The company also authorized a $300 million buyback. At a roughly $4.4 billion market cap, that buyback is not meaningless. If executed at attractive prices, it can reduce share count and enhance EPS growth.

DLocal does not need to choose between growth and capital returns: it can invest, maintain liquidity, pursue tuck-in M&A, pay a dividend, and repurchase shares. That is a much healthier profile than the market seems to give it credit for.

DLocal’s New Products Add Optionality

I would not make the DLocal thesis depend on stablecoins, agentic commerce, BNPL, or card-present payments.

The core business is already strong enough to analyze on its own: local payments, local acquiring, local card schemes, real-time networks, wallets, and settlement infrastructure.

The newer products are upside.

BNPL can improve conversion and potentially lift take rates. Stablecoins could create treasury and settlement opportunities. Card-present payments could open up more use cases in certain verticals. Agentic commerce could eventually increase transaction volume if AI agents start initiating more purchases.

But none of that needs to happen for the investment case to work.

Pedro Arnt, DLocal’s Chief Executive Officer, was honest about agentic commerce: no one really knows exactly how it will play out yet. I think that is the right answer.

The important point is that even if the way payments are initiated changes, the transaction still has to settle locally. An AI agent buying something in Brazil may still need Pix, a local card, a local wallet, or some form of regulated on/off-ramp.

The front end of payments may change, but the local execution layer still has to work.

The Main Risks to the DLocal Thesis

The risks here are not small.

• Take-rate compression could prove more damaging than management expects, especially if large merchants keep gaining pricing leverage.

• Operating leverage may not show up in the second half of 2026.

• Working capital could remain harder to forecast than investors want.

• Regulatory changes, tax issues, FX volatility, and customer concentration can all create noise.

• Competition from Adyen, Stripe, local processors, wallets, banks, and stablecoin infrastructure could also pressure parts of the business.

• And because DLocal still trades with a trust discount, any messy quarter can hit the stock hard.

This is not Visa. It is a higher-volatility emerging-market payments business that requires more monitoring.

That is also why the valuation still looks reasonable.

What I Want to See Next

I do not own DLocal yet, but it is moving higher on my watchlist.

Patience is its own discipline in Kung Fu, same as investing. You do not step into a strike before your stance is set. The setup is getting more attractive, but I want to see a few things continue to play out.

First, gross profit dollars need to keep compounding even if take rates continue to fall.

Second, operating leverage needs to show up in H2. Management has been clear that H1 is weighed down by the annualized cost of prior investments. That explanation is fine for now, but it needs to convert into better margins later this year.

Third, free cash flow should normalize as working-capital timing reverses.

Fourth, DLocal needs to keep proving that growth is broad-based across countries, verticals, merchants, and products.

Finally, capital allocation needs to stay disciplined. Buying back stock at discounted multiples can be very accretive, but only if the business keeps producing the cash to support it.

If those pieces hold, DLocal may deserve a higher multiple than it gets today.

Final Thoughts

DLocal is not a perfect story. That is part of the opportunity.

The stock still looks like a damaged fintech. The business looks more like a profitable emerging-market payments infrastructure company scaling through the noise.

TPV is growing rapidly, gross profit is hitting new records, and NRR remains excellent. The balance sheet is strong, and capital returns are improving.

Now the key test is operating leverage.

If management delivers better margins in the back half of 2026, DLocal could start to earn back market trust. If it does not, the stock probably stays in the penalty box.

That is what makes this setup interesting to me: ugly chart, improving fundamentals, lingering market distrust, and a valuation that still does not assume everything goes right.

I am not ready to call it a layup, but I do think DLocal is becoming one of the more interesting profitable growth stories in fintech.

The market is still asking whether DLocal deserves to be trusted again and the numbers are starting to make a decent argument that it should.

Disclosure: I do not currently own shares of DLO, but it is on my watchlist and I am considering whether to start a position. This is not financial advice. Do your own work.

For paid subscribers, I go much deeper.

The public thesis is that DLocal looks better than the stock chart suggests. But the real question is more practical: what would make this investable, what price makes sense, and what expectations are already baked into the stock?

Below the paywall, I walk through my current framework, including:

• how I’m thinking about DLO versus PayPal and Pagaya
• the owner’s earnings math
• a simple DCF
• a reverse DCF
• what growth the current price seems to imply
• my starter zone, better-buy zone, and chase-risk zone
• the specific numbers I want to see before getting more comfortable

Here is how I’m thinking about whether DLO is actually actionable.

Read more

When the 5-year stock chart says “this has not worked”

A five-year chart can be hard to unsee, especially when it’s going down to the right. I was reminded of this recently while looking at a company that has been through a rough stretch. The business had a Covid pull-forward, then a painful normalization period, then inventory issues and other disruptions that made the stock look like dead money for years. On paper, there were good reasons to keep studying it. The business did not look broken in the obvious way. Recent results were better. Margins were recovering. Revenue was moving in the right direction again. A smart investor I respect had real conviction in the name. But then I looked back at the chart, and the chart said something very different.

It said: this has not worked.

The chart earns my respect

That is the part of investing I do not think gets talked about enough. It is easy to say you should separate the stock from the business, and I agree with that in theory. A stock chart is not an income statement. It is not a balance sheet. It is not a complete view of the company’s future. But it is also not meaningless, especially when the chart has been bad for years. An ugly chart tells you people got hurt. It tells you expectations were too high at some point. It tells you trust was lost. When I am looking at a stock in my mid-50s, with real money that took decades to build, I cannot just wave that away and pretend the past does not matter.

That does not mean the chart gets the final word. It means the chart earns my respect before I move forward.

In martial arts, you learn pretty quickly that fear is not always the enemy. Sometimes fear is your body telling you to pay attention. If someone is moving toward you with force, you do not close your eyes and hope your form is good enough. You get grounded, read what is happening, and respond from balance instead of panic. I think ugly charts work the same way. They create a reaction first, but the goal is not to stay trapped in that reaction. The goal is to slow down enough to ask whether the danger is still there.

That is where the conviction gap begins.

They cannot lend you their stomach

The gap is not between knowing nothing and knowing everything. It is between understanding why someone else likes a stock and knowing whether you can own it yourself. A good investor can show you the map. They can point out that the stock may still be carrying the memory of old problems. They can explain why the market may be focused on the post-Covid mess, the inventory correction, or the years when the story stopped rewarding people. They can show you that the business may be improving faster than the stock price suggests. That is all useful.

But they cannot lend you their stomach.

Owning the stock is different from agreeing with the writeup. Agreement feels clean when the market is closed and the latest quarter looks strong. Ownership gets tested when the next report has one messy line, or the stock drops for no obvious reason, or the same old fears come back. That is usually when borrowed conviction disappears. If I bought only because someone else sounded confident, then I am probably going to sell when that confidence is tested, because it was never really mine.

So for me, the better question is not, “Who else owns it?” It is, “Do I know why I would own it?”

That sounds simple, but it changes the process. I am not trying to prove the chart is wrong just because the stock is down. I am trying to understand what went wrong, whether that damage was temporary or lasting, and what has changed enough to make the next five years look different from the last five. Sometimes the answer is that nothing important has changed. The business is weaker, the old growth rate is gone, competitors have caught up, or the stock is still priced for a version of the company that no longer exists. In that case, the ugly chart is not an opportunity. It is a warning.

When a bad stock chart is not a broken business

Other times, the business may have been delayed more than destroyed. Covid pulled demand forward. Customers over-ordered. Inventory had to be worked down. Costs moved around. Investors got tired of waiting. Then, quietly, the numbers start to improve again. Sales recover. Margins come back. Cash flow starts to look healthier. The company begins to look less like a broken story and more like a business that had to digest a bad cycle.

That is where it gets interesting, but also uncomfortable. We all say we want to buy when expectations are low, but when expectations are actually low, it rarely feels good. The chart looks terrible. The story has baggage. The comments are cautious. Nobody is handing you certainty. If certainty were already there, the opportunity would probably be gone.

The same pattern can show up in bigger names. Adobe and Intuit charts reflect AI fear, not necessarily AI damage. Same problem, larger scale.

The chart may remember the old business

That is the point I keep coming back to. A chart can remember the old business longer than the business itself does. Sometimes that memory is deserved. Sometimes the market is correctly saying the old thesis is gone. But sometimes the chart is still carrying pain from a period that may no longer define the company in front of you.

With the company I was studying, I did not buy. Not because the business looked broken, but because when I asked myself what went wrong, what is better now, what still worries me, and what would make me change my mind, I could not answer the last one clearly enough. That was the tell. It was not the chart that stopped me. It was the honest recognition that I did not yet have my own conviction, only borrowed interest. That is a very different reason to wait.

Part of what held me back was not the chart at all. It was the next layer of research. I wanted to understand whether the product still mattered to the end customer, whether competing technologies were improving, whether a recent acquisition actually strengthened the company’s position, and whether ongoing legal costs could become more than just a temporary annoyance. Those are not reasons to dismiss the business, but they are reasons to slow down. A recovering chart and a recovering income statement are encouraging, but if I cannot clearly explain the competitive threat and what would reduce it, I am not ready to call the conviction my own.

Finding your own center before capital moves

F.L.O.W. Investing, to me, sits in that space between reaction and response. It is not about ignoring risk, and it is not about blindly copying conviction from someone smarter. It is about staying balanced long enough to decide whether the stock is still broken, or whether the business is quietly getting better while investors are still staring at the old damage.

In Kung Fu, balance does not mean standing still. It means staying centered while something is coming at you. Investing feels similar. The ugly chart pulls you one way. Someone else’s conviction pulls you another. The work is finding your own center before capital moves.

That is the conviction gap.

And sometimes, if the evidence is real and the price still reflects the old pain, that is where the opportunity begins.

Tell me in the comments which other stocks in your watchlist or portfolio look similar.

Keep Moving,

TuDi

Disclaimer

The information in this article is provided for informational and educational purposes only.

The information is not intended to be and does not constitute financial advice or any other advice, is general in nature, and is not specific to you. Before using this article’s information to make an investment decision, you should seek the advice of a qualified and registered securities professional and undertake your own due diligence.

None of the information in this article is intended as investment advice, as an offer or solicitation of an offer to buy or sell, or as a recommendation, endorsement, or sponsorship of any security, company, or fund. The author is not responsible for any investment decision made by you. You are responsible for your own investment research and investment decisions.

Part 1 focused on the business. D-BOX makes haptic motion systems used in movie theaters, racing simulators, simulation/training, and some home entertainment use cases.

• D-BOX has crossed C$50M.

• Gross margins are above 50%.

• Operating income has turned positive.

• Cash flow is real.

• The balance sheet has more cash than debt.

• Cinemark is expanding D-BOX screens in the United States.

• F1 Arcade gives the company another commercial path outside theaters.

I waited for the full fiscal 2026 results before writing this because D-BOX was right at the point where the next report mattered. If the numbers faded, Part 1 would have looked more like a fun product story. If the numbers held, the business would deserve a more serious owner’s earnings analysis.

The full-year results were strong.

D-BOX reported record revenue, record adjusted EBITDA, record royalties, and a much stronger balance sheet. It traded as high as C$1.03 after the report, with volume running several times above its recent average.

After the move, does D-BOX still leave enough room for a good return? That’s the question.

Paid subscribers get early access to new deep dives, full Part 2 valuation work, F.L.O.W. models and tools, owner’s earnings frameworks, reverse DCF templates, scenario analysis, thesis breakers, buy/watch/avoid conclusions, and monthly research notes — including companies I researched but ultimately placed in the “Too Hard” or “Not Yet Understood” pile.

Read more

D-BOX Technologies is a small Canadian company built around one simple idea: screens can become physical experiences.

The company is best known for movie theater seats that move, tilt, and vibrate with the action on screen. A car chase can rumble through the seat. A spaceship launch can shake underneath the viewer. A superhero landing, a dinosaur attack, or a racing scene can become physical instead of only visual. Anyone who has tried a theater seat with extra bass, vibration, or motion already understands the basic idea. It can sound gimmicky until the experience actually adds something.

D-BOX goes beyond vibrating chairs. It designs haptic motion systems, which means hardware and software that translate movies, racing simulators, training programs, and immersive entertainment into physical motion. The same basic technology can show up in a Cinemark theater, an F1 Arcade racing simulator, a training system, or another commercial entertainment venue.

That is what made the business worth a deeper look to me. A theater can install a few D-BOX rows and charge more for those seats. I am used to thinking about land-and-expand models in software, where a company starts small with a customer and grows over time if the product works. D-BOX seems to have a physical version of that same idea. A theater can test a few rows. Moviegoers try it. If the seats sell well at a premium price, the theater has a reason to add more screens or expand into other locations. If nearby competitors see that working, they may feel pressure to upgrade their own premium experience too.

The same logic can apply outside theaters. A racing venue can use D-BOX to make a simulator feel more like a real car. A training customer can use motion to make practice feel closer to real equipment. The product still sounds unusual, but the use cases are easy to understand once it is viewed as more than a movie chair.

For years, D-BOX’s financial results were inconsistent. Now the numbers look different. Revenue is above C$50M. Gross margins are above 50% and operating income has turned positive. The balance sheet has more cash than debt. Over the last twelve months, the company generated about C$11.5M of cash from operations while spending only about C$1.1M on capital expenditures and about C$0.3M on intangible investment. That leaves close to C$10M of owner’s earnings before any deeper adjustments. Cinemark is expanding D-BOX screens in the United States. F1 Arcade gives the company another path outside movie theaters.

That is why this one caught my attention.

The simple business version is this: D-BOX sells the hardware, licenses the motion code, and earns recurring-style revenue from equipped theaters. This is where the business starts to become more than a chair company.

Why the business model is better than it sounds

D-BOX has two main revenue streams.

The first is system sales. These include haptic seats, bases, actuators, controllers, servers, and other equipment sold, leased, or financed into theaters, sim racing centers, training systems, and partner products.

The second is rights for use, rental, and maintenance revenue. That is the part tied to D-BOX Haptic Code and installed theater systems. The company’s MD&A describes its revenue streams as hardware sales or leasing plus licensing of D-BOX Haptic Code in equipped theaters, along with maintenance revenue.

The recurring revenue changes the story. Each new installation can create upfront system revenue, then add to the base of theaters that can generate rights, rental, and maintenance revenue over time.

The theater owner does not have to rebuild the whole theater. Cinemark describes D-BOX as customizable motion seating, and says D-BOX is usually limited to a few rows, often 20 to 30 seats.

Cinemark’s customer-facing language helps explain why the product may be easier to sell than it sounds. D-BOX is marketed as a customizable premium seat, where viewers can control the intensity and feel movement, vibration, and texture synchronized with the movie. Cinemark also separates it from 4D formats that use mist, smoke, scents, and other environmental effects. That distinction matters because D-BOX can feel like a premium upgrade without turning the movie into a full theme-park ride.

A theater can try the product in a limited way. Customers vote with their wallets. If demand shows up, expansion becomes a much easier decision.

That matters because theaters have a problem everyone understands. A lot of movies are easy to watch at home now. The couch is comfortable. Streaming is convenient. Food is already in the kitchen. The theater has to give people a reason to leave the house.

Premium formats are one answer. IMAX gives people a bigger screen and better presentation. Dolby Cinema improves picture and sound. Recliners make the theater more comfortable. Dine-in theaters turn the movie into more of a night out. 4DX adds motion and environmental effects. ScreenX expands the visual field.

D-BOX sits in that same race to make moviegoing feel worth the trip.

Why the movie slate matters

D-BOX benefits from movies people want to feel. The best fit is obvious: action, sci-fi, superhero films, animation, racing, horror, and big franchise movies where the experience itself matters.

Management has pointed to titles such as Mission: Impossible, Lilo & Stitch, Jurassic World: Rebirth, Superman, Wicked: For Good, and Avatar: Fire and Ash as part of a stronger movie environment. Those are exactly the kinds of films where a seat that moves with the action can make sense.

D-BOX said Q3 royalties were helped by major franchises including Moana, Sonic the Hedgehog, The Lion King, and Venom. That gives a clear view of the model. The better the event movie cycle, the more opportunity D-BOX has to show value inside theaters.

D-BOX thrives on event movies. The business needs enough films with speed, scale, impact, and spectacle to keep the format relevant, keep theaters interested, and keep premium-ticket demand alive.

The Cinemark expansion caught my attention

In May 2025, D-BOX and Cinemark announced an expansion adding more than 70 D-BOX haptic-enabled screens across as many as 25 Cinemark theaters in the United States over 18 months. The release said the rollout would mostly be in theaters that had not previously had D-BOX, and called it one of the largest multi-site expansions of D-BOX screens in recent years.

A major theater chain does not add 70-plus screens by accident. It still has to work. It still has to produce good returns for the theater operator. But Cinemark’s willingness to expand suggests that D-BOX is doing something useful enough to earn more floor space.

It also creates a possible competitive pressure. If one theater in a local market has D-BOX and another does not, some customers may choose the theater with the better experience for certain films. Theaters are competing with each other and with the couch, and D-BOX gives them another way to make moviegoing feel like an event.

The F1 Arcade angle makes the story less dependent on theaters

At first, I thought this was mostly a movie theater stock, but the F1 Arcade relationship makes the sim racing side more interesting. D-BOX says its partnership with F1 Arcade makes it the haptic technology supplier for F1 Arcade racing simulators and creates a path for D-BOX haptic products to be featured in all existing and future F1 Arcade locations.

F1 Arcade has also said it plans to open more than 30 locations globally by the end of 2027. That does not guarantee a large revenue stream for D-BOX. Venue rollouts can slow and partners can change plans. Consumer interest can fade. But it does give D-BOX a clearer commercial use case outside theaters.

The important piece is the repeatable venue model. Supplying haptic systems into a concept that can open across major cities is much more interesting. If each location needs dozens of simulators, D-BOX can grow through a partner’s expansion rather than trying to sell expensive consumer hardware one customer at a time.

That gives D-BOX three shots on goal:

premium movie theaters

commercial sim racing venues

professional simulation/training

The theater business is the current center of gravity, but F1 Arcade shows the company may be more than that.

The serious side: simulation and training

The training business is less flashy than Superman or F1 Arcade, but it deserves a closer look.

D-BOX serves simulation and training customers in areas like automotive, transportation, logistics, aviation, construction, and certain military applications. The logic is straightforward. Training on real equipment can be expensive, dangerous, or impractical. A better simulator can help people learn skills in a controlled environment.

This segment has not been the strongest recently. For the first nine months of fiscal 2026, simulation and training system sales decreased 11%. That needs to be watched.

Still, the longer-term logic makes sense. A theater customer buys D-BOX because it may improve the entertainment experience. A training customer buys haptics because realism can make practice more useful. That may create a more durable use case over time if D-BOX can execute. For now, I would treat simulation and training as optionality. It is part of the upside, but the recent numbers do not support making it the center of my thesis.

Management has cleaned up the business

The company had years of uneven performance. Revenue fell hard during COVID. Profitability was weak. The business had too many signs of a small company that might always be “almost there.” The recent numbers show a better version of the company.

D-BOX has become more focused. It exited lower-margin direct-to-consumer hardware, which hurt the “other” revenue category but improved the quality of the business mix. The MD&A says gross margin improved partly because of that exit and because of a higher share of rights for use, rental, and maintenance revenue. D-BOX appears to be focusing more on the channels where the economics are better.

D-BOX still has a real home-entertainment business through the HaptiSync Hub, D-BOX Connect, an $89-a-year subscription for existing customers in Canada and the U.S., more than 3,000 coded titles, and a reseller network. But management does not break out home revenue in current filings, and the best public proxy is the mixed “Other” bucket, which was about C$2.0M for the first nine months of fiscal 2026 and also includes theme parks, arcades, museums, peripherals, and logistics. So home looks more like active optionality and installed-base monetization than a core driver of the thesis.

The balance sheet also looks much stronger. As of December 31, 2025, D-BOX had C$16.2M in cash, total indebtedness of only C$0.4M, and working capital of C$22.4M.

That gives management room to operate. It also reduces the risk that shareholders get diluted just to keep the lights on.

There has also been a leadership change. D-BOX confirmed Naveen Prasad as President and CEO in August 2025, as part of a leadership realignment focused on growth and execution. That puts the company in a new phase.

The last phase was about proving D-BOX could survive and turn profitable. The next phase is harder in a different way. The company has to show that the improved margins, cash flow, and partner momentum can continue.

Competition is real

D-BOX has competition from several directions.

The closest theater competitors are 4DX and MX4D. Those formats also use motion seating, often with added environmental effects like wind, water, scent, smoke, or lighting. They can be more intense than D-BOX and more like a full special-effects auditorium.

D-BOX’s advantage: modularity. A theater can install a limited number of D-BOX seats inside an auditorium rather than committing the whole room to a full effects format.

Then there are the broader premium formats: IMAX, Dolby Cinema, ScreenX, Cinemark XD, AMC Prime, Regal RPX, recliners, dine-in seating, and other theater upgrades. These do not all do the same thing, but they compete for the same theater budget and the same premium moviegoing dollars.

The bigger competitor is still home entertainment. This is why I think about D-BOX as part of the broader effort to make going to the movies feel worth it again. D-BOX needs to keep proving that its motion seats generate enough customer interest and theater economics to justify more installations.

The moat is small but defensible

D-BOX’s moat rests on a few practical advantages: an installed base, content-coding experience, theater relationships, a modular sales pitch, and a technology platform that can move across theaters, sim racing, training, and location-based entertainment.

The first part is the installed base. D-BOX active screens reached 1,135 as of December 31, 2025, up from 1,006 the prior year.

The second part is content coding. D-BOX’s value comes from matching movement to content. That requires software, content relationships, and experience.

The third part is theater relationships. Cinemark’s expansion gives D-BOX more credibility. Theater chains do not roll out premium formats casually.

The fourth part is the modular setup. If D-BOX can be installed in a few rows and tested before expansion, the sales pitch becomes easier.

The fifth part is the platform possibility. The same haptic technology can serve theaters, sim racing, training, simulation, and location-based entertainment.

This moat still has to prove itself. The real evidence will show up in repeat orders, screen growth, recurring revenue growth, partner expansion, and margin durability.

The financial inflection is the reason this matters

For the nine months ended December 31, 2025, revenue grew 26% to C$42.9M. Adjusted EBITDA grew 112% to C$12.1M. Net profit before income taxes increased to C$9.2M from C$3.2M the year before. Operating leverage is strong.

Gross margin improved to 54% for the first nine months, up from 52% the year before. The company credited a better mix of rights for use, rental, and maintenance revenue, plus the exit from lower-margin direct-to-consumer hardware.

Cash flow also improved. Cash from operating activities was C$10.1M for the first nine months, compared with C$5.3M the year before. Investing cash outflow was only C$0.6M.

That is a major difference from many small-cap stories. D-BOX already shows profit, not promises. The financials now look meaningfully different from the old version of the company.

The bull case

The bull case is that D-BOX keeps adding theater screens, Cinemark’s U.S. rollout works, other exhibitors see the value and expand, big movie slates support premium formats, rights for use, rental, and maintenance revenue keeps growing, F1 Arcade and other sim racing venues add another growth path, simulation and training eventually stabilizes, expenses stay controlled, and cash keeps building.

A company with a market cap around C$187M only needs the market to believe the business is larger, more durable, and more profitable than investors previously thought.

That is the opportunity. The stock can work if the market sees D-BOX as a profitable haptic technology company with recurring-style theater revenue, commercial sim racing exposure, simulation optionality, and a clean balance sheet. That re-rating has already started. The next part has to be earned.

The bear case

The risks are clear.

The stock has already moved, a lot.

It still trades under one Canadian dollar, but that does not automatically make it cheap. The company has more than 222 million shares outstanding. At around C$0.82 the market cap is about C$187M.

Tariffs are another risk to watch. D-BOX is a Canadian company selling hardware into international markets, including the U.S., so changes in trade rules can affect costs, order timing, or customer decisions. Management has said the U.S.-Canada tariff situation would be a headwind, though it was still too early to quantify the impact. That adds uncertainty around near-term margins and timing.

The theater business still depends on theater operators having confidence and capital. A weak slate, slower premium spending, or pressure on theater economics could slow installations.

Competition can also pressure the story. 4DX, MX4D, IMAX, Dolby, ScreenX, premium recliners, and exhibitor-owned formats all compete for attention and capital.

The headline P/E also needs adjustment. D-BOX reported strong net income, but part of that profit came from a C$6.4M deferred tax recovery. In plain English, that means an accounting tax benefit boosted earnings for the period. It does not erase the turnaround. It just means the reported P/E makes the stock look cheaper than it may be on normal earnings. For valuation, operating income, EBITDA, and cash flow give a cleaner view of what the business is actually earning.

Why this stock is easy to miss

Many investors decided years ago that theaters were dying. Others will see the phrase “moving movie seats” and stop there. That is understandable. The product sounds odd, the stock still trades under one Canadian dollar, and D-BOX spent years with inconsistent financial results.

The business looks different after a closer look. Revenue is real. Margins are better. Operating income has turned positive. Cash flow has improved. The balance sheet has net cash. The theater footprint is growing. Cinemark is expanding D-BOX screens in the United States. F1 Arcade gives the company another commercial path outside theaters.

That combination is enough to keep going.

This is still a small, risky company. The stock has already moved a lot. The next report matters. But the business has crossed from a strange product story into something more measurable. That is the point where a deeper valuation review becomes worthwhile.

F.L.O.W. Classification

Ignored Inflection Stock

D-BOX is still early enough to carry risk, and far enough along to deserve serious study. It belongs in a different bucket from proven compounders like Visa, Intuit, or Brookfield. The business has crossed into profitability, the balance sheet is clean, and cash flow has improved.

That puts D-BOX in a more interesting middle ground.

In Part 2, for paid subscribers, I’ll go deeper into owner’s earnings, valuation, reverse DCF, margin of safety, and whether the current price leaves enough room for a good return.

The seats move. Let’s see if the numbers move us.

Keep Moving,

TuDi

Disclaimer

The information in this article is provided for informational and educational purposes only.

The information is not intended to be and does not constitute financial advice or any other advice, is general in nature, and is not specific to you. Before using this article’s information to make an investment decision, you should seek the advice of a qualified and registered securities professional and undertake your own due diligence.

None of the information in this article is intended as investment advice, as an offer or solicitation of an offer to buy or sell, or as a recommendation, endorsement, or sponsorship of any security, company, or fund. The author is not responsible for any investment decision made by you. You are responsible for your own investment research and investment decisions.

There is a particular kind of missed stock that sticks around longer than the others. Not the random name that spiked on news I never followed. Not the stock that appeared on a screen for a day. The one that really bothers me is the company I actually understood, where the thesis made sense, the price was not absurd, yet, and I had enough conviction to be interested, but never pulled the trigger.

Rocket Lab is that stock for me.

A local, offline investment group I am familiar with was looking at it around $30 or $40. The space infrastructure story already held up. Rocket Lab was not some vague speculative launch company. It had real customers, real execution, a growing launch cadence, a Space Systems business gaining traction, and the possibility that Neutron could eventually change the company’s scale entirely. Risky, yes. But the kind of risk that belonged in a small long-term allocation, not just a swing trade that banked me a few grand.

I did not need a full position. What I needed was a starter, and I did not buy one.

Why a Starter Position Changes Everything

A starter position is not a bet that I’m 100% right this week. It is a way to stay connected to an idea while I keep learning. There is a meaningful difference between watching a stock for six months and owning even a small amount of it for six months. Watching keeps the whole thing abstract. Owning changes how closely I pay attention.

When I own even a small slice, I read the earnings releases differently. I notice when management guidance shifts. I feel the volatility and learn whether I can actually handle it. A starter earns its place because it keeps the idea alive and keeps me honest.

That would have been the better Rocket Lab approach. Buy a starter when the thesis was visible but still uncertain. Then make the company earn every additional dollar.

How to Categorize Stocks Before You Buy

Every stock deserves a mental category before it receives capital.

VTI belongs in a foundation bucket, broad compounding exposure that can usually be held through normal market volatility. A profitable electrical equipment company belongs somewhere very different from an unprofitable small modular reactor startup. A speculative quantum play is not in the same neighborhood as a high-quality industrial compounder. A biotech catalyst trade has almost nothing in common with a 15-year holding. The bucket decides the sizing, the patience, and when to exit.

A foundation position can absorb volatility because that is what it was built for. A starter position can sit through rough patches because the thesis is still developing and the size is controlled. A swing trade cannot receive that same patience. When a failed swing trade quietly gets reclassified as a long-term investment, it can end badly.

Rocket Lab around $30 or $40 was an early asymmetric bet. Whatever it is today after a significant move is a different decision. The company may still be excellent and the long-term story may be stronger than ever. But buying because I cannot stand having missed it is not analysis. That is emotional repair.

Regret may explain why some stocks are tempting, but you still need a framework to keep yourself in check.

A Simple Framework for When to Open a Position

A starter position makes sense when the idea is good enough to keep studying, but still too uncertain for a full position.

That usually means the theme has staying power, the company appears to be one of the stronger ways to participate, and there is enough evidence behind the business to deserve attention. The risks are still real. The company may be early, the stock may be volatile, or the valuation may be hard to pin down. That is why the first buy should be small.

The purpose of a starter is to keep the idea active without pretending the full thesis has already been proven. If the company keeps executing, more capital can follow. If the thesis weakens, the damage stays limited.

For most individual investors, a starter might be 0.5% to 1% of a portfolio. In real dollars, maybe $2,500 to $10,000 depending on account size and the risk profile of the business. The point is not to maximize the first buy. The point is to own something real that can be studied, followed, and added to only when the company earns more capital.

That approach sidesteps two traps at once. It stops the endless waiting for certainty that never arrives, and it stops the over-commitment to a company that has not yet been proven. It also converts regret into structure instead of letting regret run the next decision.

AI Power Demand: The Real Opportunity and the Emotional Trap

The current version of this temptation may be energy infrastructure.

The logic is easy to understand. More AI means more compute, and more compute means more electricity. That pushes the story beyond chips and software into the physical infrastructure behind the data center: generation, transmission, substations, transformers, cooling systems, grid upgrades, and the labor needed to build it all. The theme is legitimate. The U.S. Energy Information Administration has projected U.S. power demand rising from a record 4,195 billion kWh in 2025 to 4,379 billion kWh in 2027, with AI and cryptocurrency data centers helping drive much of that growth.

Where investors can get into trouble is treating the theme as a single basket.

The market tends to do this quickly. It hears “data centers need power” and starts grouping together nuclear operators, fuel cells, uranium names, Bitcoin miners building AI infrastructure, grid equipment manufacturers, and early-stage reactor developers. Some of those companies may be excellent. Some may work as trades. Others may simply have the right words attached to businesses that still need a lot to go right.

The better question is which companies can turn power demand into durable earnings. That narrows the field quickly. Revenue growth is not enough. The business also needs pricing power, execution capacity, a reasonable balance sheet, and a stock price that has not already priced in years of perfect demand.

Energy and Power Stocks Worth Watching Now

These are not permanent buy prices. These are just my current working zones based on today’s valuation, the quality of the business, and the role each company might play in a portfolio.

Constellation Energy (CEG): Core AI Power Exposure

Constellation owns nuclear generation, which puts it in a narrow group of companies that can offer large-scale, reliable, carbon-free baseload power. Q1 2026 adjusted operating EPS came in at $2.74 versus $2.14 a year earlier, and the company reaffirmed full-year adjusted EPS guidance of $11 to $12.

Around $267, with a market cap near $96.5B and a trailing P/E around 26.7x, it is not cheap. It is also not speculative. This looks like the cleanest AI-power holding for a long-term account. I would be more interested in starting or adding on pullbacks into the mid-$240s or lower.

Vistra (VST): Higher-Beta Power Exposure

Vistra carries more commodity and merchant power exposure than Constellation, which means more upside leverage and more volatility. Q1 2026 net income was $1.029B, adjusted EBITDA hit $1.494B, and the company reaffirmed 2026 EBITDA guidance of $6.8B to $7.6B with free cash flow guidance of $3.925B to $4.725B.

Around $140, with a market cap near $47.8B and a P/E around 23.4x, Vistra is still a serious candidate. I would size it smaller than CEG because the earnings stream can be more cyclical. Under $130 increases margin of safety.

Eaton (ETN): Long-Term Electrification Compounder

Eaton sells the equipment that controls, moves, and manages electricity. That is highly relevant to data centers, grid upgrades, and industrial electrification, but it is a different angle than generation. This is a quality compounder, not a pure AI-power trade.

Around $399, with a market cap of roughly $155B and a P/E around 39x, the stock already prices in a lot of quality. I like the business more than the current entry point. The $340 to $360 range would make the risk/reward more attractive. This belongs in a long-term wealth-building bucket, not a quick trade.

MYR Group (MYRG): Picks-and-Shovels Electrical Contractor

MYR may be the most interesting boring idea on this list. It handles electrical construction, including transmission, distribution, substations, and commercial and industrial buildouts. If data centers and grid infrastructure keep expanding at the current pace, the actual physical work has to be done by companies with specialized crews and real execution capacity.

Around $467, with a market cap near $7.3B and a trailing P/E around 51.5x, valuation is the problem. The business angle is compelling. The price is less forgiving. The $375 to $425 range is where the risk/reward starts to look more interesting. At current levels, this is small starter only, or simply a watchlist name until the price cooperates.

GE Vernova (GEV): Broad Power Equipment Leader

GE Vernova has exposure across gas power, grid equipment, and the physical energy systems that AI infrastructure increasingly depends on. In Q1 2026, the company reported orders of $18.3B, up 71% organically, backlog growth of $13.0B sequentially, revenue of $9.3B, up 16%, and Gas Power equipment backlog plus slot reservation agreements rising from 83 GW to 100 GW. Management also said it now expects that figure to reach at least 110 GW by year-end 2026.

Around $1,049, with a market cap near $285B and a P/E around 30.7x, the business momentum is genuinely strong. The stock is also very widely owned at this point. This is a watch rather than a chase. Below $950 would be a better place to study it again.

The AI-power theme is real. That does not make every stock attached to it worth buying today.

For a long-term account, especially one recovering from past mistakes or drawdowns, the goal should be controlled compounding. The temptation is to look for the next stock that can double quickly. That is usually where the damage starts. A better approach is to sort the opportunity by bucket before deciding whether any capital should move.

Foundation holds: VTI, VUG, broad index exposure.

Quality power infrastructure: CEG, ETN, GEV.

Higher-beta power exposure: VST.

Picks-and-shovels: MYRG.

Speculative only: OKLO, BE, IREN, and similar names. Small size, continual monitoring.

This is the difference between interest and action. A company can move onto the watchlist quickly, but capital should move only when the category, size, and price all make sense.

What the Rocket Lab Miss Actually Teaches Me

The Rocket Lab miss taught me one thing: build a better process for the next good idea instead of trying to repair a mistake at a much higher price.

When a real theme appears and a good company hasn’t been fully figured out by the market yet, a starter position can make sense. Keep the size honest. Let the business earn the next buy with actual results.

If a stock has already run before I act, I don’t want to buy it just to quiet the regret. That’s how a missed opportunity becomes a forced decision.

Missing a winner hurts, but it’s still useful if it changes how I approach the next one. The next time a theme makes sense, the company fits, and the price isn’t already ridiculous, it doesn’t have to be complicated: take a small starter position and keep paying attention. Of course with space stocks, you only have to be patient for a major pullback, right?

Keep Moving,

TuDi

Subscribe now

Disclaimer

The information in this article is provided for informational and educational purposes only.

The information is not intended to be and does not constitute financial advice or any other advice, is general in nature, and is not specific to you. Before using this article’s information to make an investment decision, you should seek the advice of a qualified and registered securities professional and undertake your own due diligence.

None of the information in this article is intended as investment advice, as an offer or solicitation of an offer to buy or sell, or as a recommendation, endorsement, or sponsorship of any security, company, or fund. The author is not responsible for any investment decision made by you. You are responsible for your own investment research and investment decisions.

A great business can start to feel like it should be bought at almost any price. A pullback can look like proof that the stock is cheap. A strong story can start to feel like conviction, even when the price still does not leave enough room for a good return. Zoetis is a good example here, a name Pieter has bought, and one that has dropped sharply since then. I am still watching it patiently rather than treating the drop alone as a buy signal.

That is how a portfolio can end up filled with excellent companies and still produce mediocre returns. The businesses may be doing everything right, but the starting price still matters. Sometimes it matters more than the business quality itself.

That distinction matters more now because the market is not giving an obvious signal. It is not broadly cheap, but it is not acting completely euphoric either. Many of the world’s best companies are trading closer to fair value than obvious bargain territory. Some can still work well over the long term, but only if execution remains strong and expectations stay reasonable. A smaller group offers something more interesting, where the business is good enough, and the price low enough, to deserve more capital.

Bruce Lee’s line, “hack away the unessential,” fits this well. The market is full of interesting stories, strong businesses, and tempting pullbacks, but not all of them deserve capital at the same time. The work is to cut away the names that are merely interesting and focus on the few where patience, price, and business quality finally line up.

That is where the F.L.O.W. framework helps.

Every stock sits in a state. Some deserve new capital. Some deserve patience. Some need more work. Some belong outside the F.L.O.W. octagon entirely.

Those states change over time. Sometimes the business has not changed much at all, but the stock has moved enough to change the likely return. The opposite can happen during periods of fear, forced selling, or broad market weakness.

The goal is to decide whether the business is good enough, and the price low enough, to deserve more capital.

Actionable: Stocks That May Deserve Capital Now

Actionable does not mean safe. It means the business looks strong enough, and the price low enough, to justify putting more capital to work.

Brookfield Stock Analysis: Complexity Creates the Opportunity

Brookfield is one of the few names in this framework where the complexity is part of the opportunity.

The business is not easy to value in a simple way. Brookfield combines operating businesses, asset management, insurance, infrastructure, renewable power, real estate, and private equity into one large capital allocation machine. Basic numbers like revenue, earnings, or even ROIC only tell part of the story because capital is constantly moving through the system.

That turns a lot of investors away, and honestly, I understand why. Brookfield is hard to model with precision. Even investors who understand the company well can come up with very different estimates of what it is worth.

Brookfield’s engine is still understandable. The company has compounded capital at high rates for decades by moving money into places where it sees better long-term returns, using permanent capital, scale, and deep operating experience across real assets. The economics are tied less to what the market thinks this quarter and more to the long-term value of the assets, the fee streams, and management’s ability to keep recycling capital well.

That puts Brookfield in Actionable. The business takes work to understand, but the quality is still there. The opportunity comes from the fact that the value is harder to measure than usual.

Kelly Partners Group Stock: Governance Risk Meets a Much Lower Price

Kelly Partners is probably the clearest example here of a business where the debate has moved away from the accounting model and toward management judgment.

The underlying business still looks attractive. Accounting work is recurring, cash generative, and tied to services that small and mid-sized businesses need in almost any economy. Kelly Partners has also continued expanding through acquisitions and geographic growth, while operating in a fragmented industry where many smaller accounting firms still need a succession plan.

The issue is that investors are no longer looking only at the business model.

The margin call situation involving Brett Kelly changed the way many people see the risk. Founder behavior, personal leverage, reputation, and governance all became part of the investment case. That may not have been the focus before, but it is part of the reality now. The stock fell more than 70% from its peak as confidence broke down and forced selling added more pressure.

Governance risk is real risk.

At the same time, the stock may have fallen much faster than the business itself. If Kelly Partners keeps executing, keeps generating cash, and restores some confidence around management behavior, the current price could end up looking very attractive in hindsight.

This is not a clean, sleep-well-at-night compounder like Visa or Intuit. The opportunity comes from deciding whether the market has punished the stock more than the business deserves.

That puts KPG in Actionable, but with a smaller position size, closer monitoring, and a wider range of outcomes. The price already reflects a lot of damage, but the risk has not disappeared. Things can change quickly. A good stance matters most when balance is tested, and that is why I believe in ETFs, diversification, and a framework that keeps me honest when the market starts to feel like the sky is falling.

Intuit Stock at $395: A High-Quality Compounder Looks Actionable

Intuit is one of the cleaner examples of a high-quality compounder that finally moved close enough to a reasonable entry point.

I bought more Intuit around $395, averaging up from an original cost basis near $70. That price matters because it lined up closely with my prior valuation work. In the deep dive, I estimated fiscal 2025 owner’s earnings at roughly $14.54 per share after treating stock-based compensation as a real owner cost. Around $399, the stock offered an owner’s earnings yield of roughly 3.6%, and the math suggested the business needed to grow owner’s earnings about 12% a year over the next decade to make the price work.

That is not a screaming bargain if growth slows. It is also not a price that requires fantasy assumptions.

Intuit remains deeply embedded in financial workflows where mistakes matter. QuickBooks is not simply accounting software for small businesses. It is tied to payroll, payments, invoicing, bookkeeping, financing, and financial reporting. TurboTax remains a dominant tax platform. Credit Karma gives Intuit a year-round relationship with consumers. ProTax keeps the company connected to professional accountants who influence which tools businesses use.

The concerns are real. AI could pressure parts of software pricing. Government tax filing remains a policy risk. Low-end accounting competition is not going away. Credit Karma is tied to lending cycles. Those risks matter, but they do not all carry the same weight.

The main question is whether Intuit can keep growing owner’s earnings at a low-teens rate through revenue growth, more services attached to each customer, mid-market expansion, modest margin improvement, and continued buybacks. At $395, that question becomes worth taking seriously. The stock no longer looked like everything had to go perfectly.

That puts Intuit in Actionable. It is an established platform where the price finally made sense again.

At $395, Intuit is close to “back up the truck” territory for a business of this quality, with one important qualification: the truck still has to be sized to the risk. The business is durable, but the price is not so low that execution no longer matters. I was comfortable buying there because low-teens owner’s earnings growth still seems realistic. For anyone who grabbed shares closer to $350, well done. Your patience was better than mine.

Stocks to Watch: Great Businesses Where the Price Still Matters

This is often the hardest category because it usually contains the businesses investors most want to own.

The company may be strong. The long-term direction may be clear. The issue is price. Sometimes a business can be excellent and still need a better entry point before it deserves more capital.

Visa Stock: A Wonderful Business Waiting for a Better Price

Visa remains one of the strongest business models in the market.

The network effects are enormous. Margins are exceptional. The long-term shift from cash to digital payments is still working in Visa’s favor, and the company continues to generate a lot of free cash flow without needing heavy capital investment.

The business is easy to admire. I just need a better price before adding much more.

At roughly current levels, Visa looks more fairly priced than cheap. The company can still do well from here, but the return depends heavily on Visa continuing to execute at a high level. That is not a bad place to be, but it is different from buying when the price leaves more room for normal mistakes.

I started a small position around $295 for that reason. I like the business, and I am comfortable owning some. But I would become much more interested in adding aggressively if the stock moved back into a range where the price left more room for a good return.

That keeps Visa in Watching. The business is durable, the long-term direction still looks favorable, and the quality is obvious. The price just is not low enough yet to make it a full Actionable idea.

LVMH Stock: Luxury Quality Still Needs the Right Entry Point

LVMH remains one of the most interesting consumer businesses in the world. It combines brand power, scarcity, pricing strength, and global reach in a way very few companies can copy.

Luxury can be cyclical in the short term, even when the long-term business remains strong. That distinction matters here.

The current environment is still mixed. China has been soft, consumers are more cautious, and the macro backdrop has pressured sentiment. But the underlying brands remain exceptional. Louis Vuitton, Dior, Tiffany, and the rest of the portfolio are not ordinary retail assets. They are cultural and aspirational assets with decades of pricing power behind them.

LVMH stays in Watching because the business quality is clear, but the entry point may still get better if consumer weakness or broader market pressure deepens. This is a company worth following closely. The price still decides how attractive the investment becomes.

Stocks That Look Too Expensive Today

Some of the best companies in the world become hard investments when the stock price already expects too much future success.

Nvidia Stock: A Great Company With a Demanding Price

Nvidia may still become one of the most important businesses of the next decade. That possibility is not hard to understand.

At current prices, Nvidia needs a lot to keep going right. Growth needs to remain extraordinary. Technological leadership needs to stay intact. Competition needs to avoid eating too much into margins in one of the most crowded and important markets in the world.

That does not make Nvidia a bad business. The company may keep executing extremely well for years. The issue is that the stock leaves less room for normal problems.

Great businesses can still become difficult investments when the price already expects greatness. Nvidia remains exceptional operationally, but the stock requires a level of future performance that leaves less margin for error.

Adobe Stock: Strong Business With More AI Uncertainty Than I Want

Adobe remains a dominant creative software platform with meaningful switching costs, strong profitability, and deeply embedded workflows.

The issue is how much AI changes the value of that position over time. If creative work becomes easier to generate, edit, and distribute outside Adobe’s ecosystem, parts of the moat that protected the company for years could slowly weaken.

That risk may be overstated. Adobe still has distribution, customer relationships, enterprise trust, and integrated tools that smaller competitors would struggle to match. The company also has a long history of adapting through major technology changes.

The stock still needs either a better price or clearer evidence that AI is strengthening Adobe’s position rather than slowly chipping away at it. Adobe may remain a very good business, but at the current price, it does not look compelling enough to call Actionable.

Stocks That Still Need More Work

Some ideas are interesting, but the path to a good return is not clear enough yet.

Palantir Stock: Big Opportunity, Harder to Judge

Palantir may ultimately become a much larger business than many investors expect. I just have a harder time separating the strength of the story from the long-term durability of the business.

The company sits at the intersection of government work, enterprise software, AI infrastructure, and data integration. The opportunity is clearly large. I am still trying to judge how durable the business will be, how profitable it can become at scale, and how much of today’s enthusiasm will turn into long-term owner returns.

Palantir may turn out to be a great business. I am just not at the point where I understand the long-term economics well enough to put serious capital behind it.

Palantir deserves a place on the research list. It does not yet deserve the same confidence as a company where cash flow, margins, customer behavior, and reinvestment returns are easier to see.

Snowflake Stock: Important Platform, Unclear Long-Term Returns

Snowflake remains one of the harder software businesses for me to evaluate because the future depends on how data infrastructure, AI workloads, and cloud spending evolve over time.

The platform clearly matters. I am just not sure yet whether that importance will translate into the kind of long-term profits shareholders need.

Competition is intense. Customer spending patterns can change. AI may increase demand for data infrastructure, but it may also change where value collects across the stack. Snowflake could end up being very important and still not produce the kind of shareholder return the stock needs.

For now, Snowflake stays in research mode. It may become more attractive if margins improve, customer spending becomes more stable, and its role in AI data infrastructure becomes easier to connect to real cash flow.

Stocks and Sectors That Are Too Hard for Me Right Now

This category is about boundaries.

Early-stage biotech, quantum computing speculation, highly promotional pre-revenue companies, and businesses where the outcome depends almost entirely on binary events often belong here.

Some of these companies will absolutely become enormous winners.

The problem is that the path from today to that outcome is too hard to evaluate consistently. The result depends more on uncertainty than on business analysis.

In martial arts, restraint is part of control. The same is true with capital. Passing keeps money available for the situations where the business is understandable, the price is reasonable, and the path to a good return is clearer.

Final Thoughts: Where Capital Belongs Right Now

Most of the time, a stock does not move between categories because the business changed overnight. It moves because the price changed enough to alter the return. The same company can be attractive at one price, merely interesting at another, and too expensive once expectations get stretched.

That is the point of the F.L.O.W. framework. It keeps a good business, a good story, and a good investment from getting treated as the same thing. The discipline is slowing down long enough to know which one is actually in front of me.

Brookfield, Kelly Partners, and Intuit are all Actionable, but for very different reasons. Brookfield is high quality but harder to measure. Kelly Partners has a real governance shadow, but the price already reflects a lot of pain. Intuit is a high-quality compounder that finally moved close enough to a price where I was comfortable buying again.

Visa and LVMH remain excellent businesses, but the price still calls for patience. Nvidia and Adobe may continue to be important companies, but the stocks need either better prices or clearer evidence that today’s expectations can be met. Palantir and Snowflake remain research projects until the economics become easier to judge.

Knowing the category before money moves is the whole point.

Keep moving,
TuDi

Subscribe now

Disclaimer

The information in this article is provided for informational and educational purposes only.

The information is not intended to be and does not constitute financial advice or any other advice, is general in nature, and is not specific to you. Before using this article’s information to make an investment decision, you should seek the advice of a qualified and registered securities professional and undertake your own due diligence.

None of the information in this article is intended as investment advice, as an offer or solicitation of an offer to buy or sell, or as a recommendation, endorsement, or sponsorship of any security, company, or fund. The author is not responsible for any investment decision made by you. You are responsible for your own investment research and investment decisions.

The main post laid out the business and why Visa currently sits in Watching. This note focuses on what today’s price is asking investors to underwrite.

Visa generated roughly $11–12 per share in owner’s earnings over the last twelve months. At around $317 per share, the starting point is straightforward. To earn a 10% return from here, the business needs to compound at roughly 10% annually over time.

That aligns with Visa’s historical performance. The business model supports it. The network remains dominant, margins are stable, and the shift toward digital payments continues to provide a long runway. Management has also been consistent in how it allocates capital, with buybacks steadily reducing the share count and reinforcing per-share growth.

Small changes in price and growth move the return quickly.

If we hold growth constant at around 10%, the return shifts meaningfully as the price changes:

Read more

Visa Inc. sits in the middle of global commerce and takes a small fee every time money moves across its network. It does not lend, it does not take credit risk, and it does not need to fund receivables with its own balance sheet. It processes transactions at enormous scale, and that scale has been built over decades in a way that would be extremely difficult to replicate. The result shows up clearly in the economics. Gross margins remain above 80%, operating margins sit around 60%, and returns on capital stay at levels most businesses never come close to reaching. There are very few companies that combine that level of profitability with that level of durability.

That is also where discipline tends to slip. Once the business becomes obvious, the focus can quietly shift from expected return to ownership itself. The thinking becomes that a company like Visa should simply be owned, and price starts to feel secondary. You can see that in the way the company is usually discussed. It is framed as a long-term compounder, a core holding, a business you buy and keep. Much of that is fair. Visa clearly benefits from the ongoing shift from cash to digital payments, and its position in that system remains unusually strong. But none of that answers the question that matters most for an investor making a decision today.

What matters is what that quality is worth from here.

The underlying engine is still straightforward. Payment volumes continue to rise as more spending moves onto digital rails. Cross-border activity adds a more profitable layer on top. Data processing and value-added services scale alongside the network. The cost base does not rise in the same way revenue does, which means incremental revenue tends to fall through at very high margins. Over time, that has produced a business that can grow at a healthy rate without requiring much additional capital to support that growth.

When you translate that into owner’s earnings, the picture stays attractive. Visa generated about $22.9B in free cash flow over the last twelve months. With roughly 1.9B shares outstanding, that works out to around $12 per share. If stock-based compensation is treated as a real economic cost, which it should be, and capital expenditures are viewed conservatively, true economic earnings still land in the $11–12 per share range. For a business of this size, that level of consistency matters.

What Visa does with that cash matters just as much as how it earns it. The business does not need large reinvestment to keep growing, so most of the excess cash can be returned to shareholders. Buybacks have been running at a level that roughly equates to a 3% annual yield, steadily reducing the share count, while the dividend adds a smaller income component on top. That is how per-share compounding continues even when the overall business is growing steadily rather than explosively. The model is doing exactly what it is supposed to do.

From here, the question is simpler than it looks. At around $317 per share, Visa trades at roughly 29 times earnings and about 25 times free cash flow, which implies a free cash flow yield of just under 4%. That is not extreme relative to its own history, and it is not obviously cheap either. The market is effectively pricing Visa for continued steady growth.

Fair value is not the same thing as a compelling return.

If you work backward from the current price using a 10% required return and a terminal growth assumption of around 2.5%, the market is effectively pricing Visa to compound owner’s earnings at roughly 10% annually. That aligns closely with its historical performance. At that level of growth, the expected return also falls in the high single-digit to low double-digit range, which leaves limited room for error.

The business itself remains intact. The network is dominant, the economics are strong, and the long-term tailwind of digital payments replacing cash is still in place. The question is whether today’s price allows that quality to fully play out.

Within the F.L.O.W. framework, this is what Watching is for. The business is understood. The model is durable. The long-term direction is clear. What is missing is not conviction in the company, but a price that creates a better imbalance between what is required and what is likely. That is where patience matters.

At roughly $11–12 in owner’s earnings per share, a 5% free cash flow yield implies a price closer to the $240 range. That is where the setup begins to change, with required growth falling below historical levels and the margin for error widening. The $240 to $260 range represents a high-conviction entry. Above that, the outcome can still be reasonable, but it depends more on continued execution than on a favorable starting point.

Some investors are comfortable owning Visa at current levels, and that position is understandable. It is a high-quality business with durable economics, and over long periods, even fair entry points can compound into solid outcomes. I opened a small position around these levels for that reason. Visa last traded in the $250 to $260 range in 2024, before moving into a higher valuation band, which helps frame where a more favorable entry has historically appeared. It reflects confidence in the business, but also an understanding that the return from here is likely to track execution rather than benefit from a favorable starting point.

Within the F.L.O.W. framework, the bar remains different. The goal is not simply to own a great business, but to enter at a point where the relationship between price and expected return creates a clear advantage. That is what separates Watching from Actionable. In some cases, exceptional businesses can still be considered actionable without a clear discount, but that depends on conviction in long-term compounding rather than price alone.

For Visa to move from Watching to Actionable, nothing about the business needs to change. The shift would come from price. At a lower multiple, the dependency on near-perfect execution falls, the margin for error widens, and the quality of the network begins to work more fully in its favor.

Until then, Visa remains what it already looks like: a dominant, durable compounding machine priced to deliver a reasonable outcome, but not an exceptional one. The discipline is not in recognizing the quality. The discipline is in waiting until the price lets that quality work harder for you.

If this kind of disciplined research adds value to your investing thinking, consider supporting the work with a paid subscription. Paid subscribers receive the valuation models, assumptions, and scenario analysis behind the research, along with early access to deep dives and ongoing research notes.

Keep Moving,
TuDi

Subscribe now

Disclaimer

The information in this article is provided for informational and educational purposes only.

The information is not intended to be and does not constitute financial advice or any other advice, is general in nature, and is not specific to you. Before using this article’s information to make an investment decision, you should seek the advice of a qualified and registered securities professional and undertake your own due diligence.

None of the information in this article is intended as investment advice, as an offer or solicitation of an offer to buy or sell, or as a recommendation, endorsement, or sponsorship of any security, company, or fund. The author is not responsible for any investment decision made by you. You are responsible for your own investment research and investment decisions.

“Interest is not conviction. Conviction is not allocation.”

From Idea to Capital

Every investment starts the same way. Something catches your attention, a chart, a product, a thread, a name that keeps appearing from your favorite X or Stocktwits posters. The problem is not finding ideas. The problem is deciding what to do with them.

There needs to be a structured bridge between interest and action. That bridge is the watchlist, not as a collection of tickers, but as a decision framework. Every idea must earn its way forward.

The framework doesn’t ask, “Should I buy this?” It asks what is missing. Patience is holding position until nothing material is missing. If something is, there is no decision to make. No urgency. No forcing.

Watchlist Framework Explained: What Each Stage Means

The five stages are not judgments on a company’s quality. They are simply a reflection of where things stand from your perspective, what is clear, what is still forming, and what is missing before capital can be put to work.

Palantir / Snowflake - Not Yet Understood
There is clearly something there, and that’s usually why the name keeps coming up, but the underlying drivers are not yet clear or stable enough to model with confidence. You can describe the business at a high level, but you don’t yet have a clean line of sight into how the economics will play out over time. At this stage, the only real action is to keep doing the work and resist the temptation to move too early.

Nvidia - Not Attractive
This is where things can get dangerous, because the business itself is not the issue. The demand is obvious, the economics are exceptional, and execution has been strong. But none of that guarantees a good outcome from the current price. When expectations are elevated, even great performance can translate into average or below-average returns. This is where discipline shows up, recognizing that a great company is not automatically a great investment at any price, and being willing to wait without forcing the decision.

Visa - Watching
Here, most of the work is already done. The business is understood, the model is durable, and the long-term trajectory is clear. What’s missing is not clarity, it’s price. You’re no longer asking whether you want to own it, you’re defining the level at which the expected return makes sense. Until that level shows up, the correct action is simply to hold position and wait.

Brookfield - Actionable
This is what it looks like when everything lines up. The business is understood, the structure makes sense, and the price reflects an opportunity where the expected return justifies capital. There are no meaningful unknowns standing in the way. These situations are rare, and they should be. When nothing is missing, the decision becomes straightforward, this is where capital actually moves.

Why Most Investors Overpay for Great Companies

The most important column in the framework is not Actionable. It is Not Attractive.

This is where most discipline is lost. A business is understood, conviction builds, and then price gets ignored. The narrative shifts from “this is a great company” to “I need to own this.” That is how returns get diluted, not through bad analysis, but through impatience dressed up as conviction.

“Understanding a business is not the same as getting paid for it.”

How Stocks Move From Watchlist to Buy Decision

The goal is not to move everything toward Actionable. Most ideas should never get there. The real value comes from understanding precisely what would need to change for a company to advance.

Not Yet Understood — Watching
Key drivers become visible; clarity on the economic model improves.

Not Attractive — Watching
Price corrects; market expectations reset to a realistic level.

Watching → Actionable
Nothing is missing. This step is rare, and should be.

How This Framework Improves Capital Allocation

The watchlist is not where capital is deployed. It is where capital is protected. Only one category leads to action: Actionable. Everything else exists to prevent premature allocation.

Ideas move left to right. Capital does not.

“Most investors look for ideas. Very few define when they’re allowed to act.”

Only a small number of names are tracked. Most time is spent in Watching, not Actionable. Actionable is intentionally limited. Capital is deployed only when nothing is missing.

This is the structure. What matters is how it actually gets used.

From Framework to Execution

This is where most frameworks fail in practice. They look clean on paper, but don’t hold up in real decisions. Execution determines the outcome, what actually moves a name from Watching to Actionable, what defines a real buy zone, and why most ideas never make it there.

Below is how this framework is used in practice: the names being tracked, the levels that matter, and what would need to change before capital is deployed.

Read more

It allows you to test how changes in growth assumptions affect intrinsic value and expected returns.

The goal is not to predict the future precisely. The goal is to understand what expectations are already embedded in a stock’s current price.

Use the model to:

• test different growth assumptions
• estimate intrinsic value
• see what return a stock might offer from the current price
• understand what growth rate the market is pricing in

Download the spreadsheet.

Updates for Paid Subscribers

I’ve made a few changes to what paid subscribers receive going forward.

Paid subscribers now receive:

• early access to F.L.O.W. Investing deep dives before public release
• the valuation models used in the research, including the Reverse DCF and Owner’s Earnings toolkit
• scenario analysis and assumptions behind the models
• periodic research notes on comp…

Read more

But lately the Too Hard pile sometimes serves another purpose. It can become a convenient place to set aside a company simply because we are not yet willing to do the work required to understand it.

When that happens, something subtle occurs.

The “Too Hard” pile in investing sometimes becomes a graveyard of future compounders.

The real challenge is not whether the Too Hard pile should exist. It should. The challenge is knowing when a company genuinely belongs there.

Understanding that distinction requires a more deliberate framework. And it’s how some of my best winners, continue to win, as my safer bets need to recover.

Why Complexity Does Not Always Make a Company Too Hard to Analyze

One of the first mistakes investors make is confusing complexity with impossibility. Some businesses operate in ecosystems that appear intimidating at first glance. But complicated does not necessarily mean unknowable.

Consider Visa. At the surface, the global payments system looks messy. There are issuing banks, acquiring banks, settlement layers, fraud protection protocols, cross-border rules, and regulatory oversight. Billions of transactions move through this network every year.

Yet the economic engine underneath it is remarkably straightforward.

Consumers swipe a card to make a purchase. Merchants pay a small fee for guaranteed payment and access to the network. Visa keeps a fraction of that transaction in exchange for providing the global infrastructure that makes the system possible.

The system itself is complex, but the economics are simple.

This distinction appears again and again in investing. Some businesses live inside complicated systems while still maintaining clear and understandable economics. Others look simple on the surface but hide fragile or unpredictable economics beneath them.

The Too Hard pile should exist for the latter, not the former.

How to Analyze a Business Model by Following the Flow of Money

The most reliable starting point in evaluating any business is the simplest question in investing:

How does money move through this company?

The question sounds basic, but it quickly reveals whether the investor truly understands the business.

Take Costco. If you analyze Costco as a traditional retailer, the margins look unusually thin. The company barely makes money on the merchandise it sells. But the moment you realize Costco is not really a store but a membership club that happens to operate warehouses, the economics suddenly make sense.

Customers pay an annual membership fee. That fee is where most of the profit comes from. The low prices on merchandise are not the main profit engine. They exist to reinforce the value of the membership and keep renewal rates high.

Once that structure becomes clear, the business becomes much easier to analyze. The key question shifts away from retail margins and toward the durability of membership renewals and customer loyalty.

When investors say a company is too hard, they often mean they cannot clearly trace this path. If it is difficult to explain who pays the company, why they pay it, and what the company must do to keep earning that payment, the business may legitimately belong in the Too Hard pile.

But if the flow of money can be described clearly, the company may already be far more understandable than it first appeared. In the full F.L.O.W. deep dives, paid subscribers can explore the valuation models and scenario analysis used to test these assumptions in detail.

When a Company Is Truly Too Hard vs. Simply Outside Your Circle of Competence

In martial arts there is a simple saying: “The mat does not lie.” Training quickly exposes whether a technique actually works or whether we are only convincing ourselves that it does.

Investing demands the same discipline. This is where intellectual honesty becomes essential. Sometimes a company is genuinely difficult to analyze. Other times the difficulty lies with the investor rather than the business.

Every investor develops familiarity with certain industries over time. A software engineer might intuitively understand cloud infrastructure. A physician might find pharmaceutical companies easier to analyze. Someone with experience in manufacturing may quickly grasp industrial supply chains.

When investors encounter an industry outside their experience, the natural reaction is often to label the business “too hard.” But the real issue may simply be distance from the domain.

A useful question to ask is whether the company would become understandable after spending several months studying the industry. If the answer is yes, the business may not belong in the Too Hard pile at all. It may simply belong in the “not yet understood” pile.

Great investors expand their circle of competence gradually by turning “not yet” into “now.”

A Simple Framework Investors Can Use to Evaluate Any Company

Before placing a company into the Too Hard pile, it helps to pause and run a simple mental filter.

The Plain Language Test.
Can the flow of money through the business be explained in two sentences of plain English? Not by repeating phrases from an investor presentation, but by describing who pays the company, why they pay it, and what the company must do to keep earning that payment.

The Must-Have Conditions.
What are the small number of conditions that must repeatedly go right for the company to succeed? If those conditions depend on unpredictable events such as scientific breakthroughs, regulatory approvals, or volatile commodity prices, the investment may legitimately be too difficult.

The Narrative Mirror.
Do the financial statements tell a consistent economic story? Over time, strong businesses reveal patterns in revenue growth, margins, and cash generation. If the numbers constantly require adjustment or contradict management’s narrative, the economics may not yet be clear.

The Fragility Factor.
Does the investment thesis collapse if your growth estimate is slightly wrong? If small changes in assumptions dramatically change the estimated value of the business, the issue may not be the company itself but the price being asked for it.

If several of these questions remain unclear after serious effort, the Too Hard pile is doing exactly what it was designed to do. But if the answers become clear after careful thinking, the company may never have been too hard at all.

It may simply have required the patience to simplify it.

Famous Investing Mistakes Caused by the “Too Hard” Pile

History is full of businesses that were once dismissed as “too complicated.”

Amazon was placed in the Too Hard pile by many investors who could not reconcile the lack of GAAP profits with the company’s aggressive reinvestment. Those who looked deeper saw a powerful cash-flow engine and the emergence of high-margin segments like AWS.

Nvidia was often dismissed as a cyclical semiconductor company by investors who did not spend the time to understand the shift toward parallel computing and artificial intelligence.

MercadoLibre was frequently labeled too difficult because of regional complexity in Latin America, missing the fact that its payments and logistics ecosystem was quietly becoming one of the most powerful platforms in the region.

None of these businesses were simple. But none of them were unknowable either.

The Real Skill in Investing: Simplifying Complex Businesses

The best investors do not avoid complexity. They develop the ability to simplify it.

Most businesses, when examined carefully enough, reduce to a few core economic drivers. Customers pay for something they value. The company must deliver that value efficiently enough to generate profit. The durability of that loop determines long-term success. Once those drivers become clear, even complicated companies begin to look surprisingly simple.

The Too Hard pile is a valuable discipline because it prevents investors from pretending they understand businesses they don’t. But it only works when it’s used honestly. No investor needs to understand every company in the market. What matters is recognizing the difference between complexity that can be simplified and uncertainty that can’t be resolved. Investing becomes much easier once that distinction is clear.

The question every investor eventually faces is simple: what belongs in the Too Hard pile today, and what simply requires deeper understanding tomorrow?

Paid Subscriber Research & Tools

Much of investing happens before conviction appears. Paid subscribers get access to the working side of that process: the models used to test assumptions, the scenario analysis behind the conclusions, and research notes on companies I’m still studying, including businesses that may currently sit in my “Not Yet” or “Too Hard” pile while I work to understand them. Not every company makes it out of that pile, but the thinking process often reveals the most important lessons.

Paid subscribers can download the F.L.O.W. INVESTING Reverse DCF & Owner’s Earnings model used to stress-test companies in these analyses. The toolkit is available in the subscriber library (watch out for the post when this goes live).

Adjust the growth assumptions to estimate intrinsic value, see what return a stock might offer from today’s price, and understand what expectations are already embedded in the market.

If this kind of disciplined research adds value to your investing thinking, consider supporting the work with a paid subscription.

Paid subscribers receive:

• early access to new F.L.O.W. Investing deep dives
• the valuation models used in the research, including the Reverse DCF and Owner’s Earnings toolkit
• the assumptions and scenario analysis behind the models
• periodic research notes on companies I’m actively studying, including businesses currently in my “Not Yet” or “Too Hard” pile

Keep Moving,

TuDi

Subscribe now

Disclaimer

The information in this article is provided for informational and educational purposes only.

The information is not intended to be and does not constitute financial advice or any other advice, is general in nature, and is not specific to you. Before using this article’s information to make an investment decision, you should seek the advice of a qualified and registered securities professional and undertake your own due diligence.

None of the information in this article is intended as investment advice, as an offer or solicitation of an offer to buy or sell, or as a recommendation, endorsement, or sponsorship of any security, company, or fund. The author is not responsible for any investment decision made by you. You are responsible for your own investment research and investment decisions.

Infrastructure businesses are valued differently than product companies. Products can grow quickly. Infrastructure embeds itself inside workflows, budgets, and regulatory frameworks. It becomes difficult to replace not because of brand loyalty, but because operations begin to depend on it.

Axon is in the middle of that transition. It is moving from a hardware vendor to the operating layer of public safety. That shift is about more than capturing budget. It is about becoming embedded in the daily workflow of agencies.

Revenue in 2025 reached approximately $2.78B. That number alone does not tell the story. What matters is how that revenue is composed and how it behaves over time.

Products revenue totaled roughly $1.58B. Services and software revenue reached approximately $1.20B. That 40% software mix represents the ratchet beginning to set. Once a department’s evidence, reporting, and AI drafting live in the Axon cloud, leaving is no longer a simple purchasing decision. It becomes operational restructuring.

Services gross profit in 2025 was approximately $891M versus $768M from products, despite lower revenue. That mix shift is not cosmetic. It is the driver of margin expansion and long-term operating leverage.

Products have grown well. Services have grown dramatically faster. That differential reshapes the economics of the company.

More importantly, the structural strength of the model is not limited to margin expansion. It rests in retention and the increasing depth of integration inside agency workflows.

Net revenue retention has been running around 125%. That means existing customers, before adding a single new logo, are expanding their spend materially year after year. The installed base is deepening its dependency. Each additional software module tightens workflow integration and raises the practical cost of replacement.

Over time, the digital footprint inside agency operations expands. Evidence management, reporting, compliance, and AI drafting become embedded within the same system architecture. Replacement becomes operationally disruptive rather than simply budgetary.

SaaS annual recurring revenue reached roughly $1.35B. Future contracted bookings sit above $14B. That backlog acts as a shock absorber. It cushions multi-year cash flows against short-term budget noise and reduces the probability of sharp revenue contractions. This is where Axon begins to resemble a vertical platform rather than a hardware vendor.

The ecosystem includes conducted energy devices, body cameras, digital evidence management, records management, AI-driven report drafting, and subscription tiers layered on top of hardware installations. Each additional module deepens integration into agency workflows. Replacing one product would require disentangling evidence storage, compliance systems, reporting software, and hardware networks simultaneously.

Switching costs in this context are operational and regulatory. They stem from workflow entrenchment, data custody requirements, audit trails, and institutional retraining, not simply from hardware replacement.

That is the core moat.

The competitive landscape remains active. Motorola Solutions operates in adjacent public safety infrastructure with scale, distribution reach, and balance sheet strength. Smaller players compete in body cameras and niche software modules. The depth of Axon’s integrated stack increases the complexity of direct displacement as the installed base expands.

Public safety technology tends to reward deep integration over pure market share. Competitive advantage builds through workflow entrenchment, recurring contracts, and expanding software layers rather than through one-time hardware wins.

The durability of the model rests on three pillars:

1. Recurring revenue scaling faster than hardware.

2. Retention consistently above 120%.

3. Workflow entrenchment that increases switching friction over time.

From a structural standpoint, the business is strong. The durability of the model is clear in the revenue mix, retention profile, and backlog visibility.

The tension emerges when a structurally strong business trades at a premium valuation alongside aggressive incentive compensation. That intersection is where enterprise strength and per-share outcomes begin to diverge.

To understand whether this is compounding for shareholders or merely scaling for the enterprise, we have to move beyond revenue and gross profit and examine the economic engine underneath.

That engine is defined by four variables:

– Operating leverage
– Capital intensity
– Stock-based compensation
– Dilution

Revenue growth without discipline in those areas can produce impressive enterprise scale while per-share economics lag behind. It resembles martial arts training in class without practicing the movement at home. Activity is visible. Compounding is limited.

From 2021 to 2025, revenue compounded at roughly 30% annually. That growth rate is exceptional. During the same period, share count increased from approximately 71.5M to 78.9M. Dilution averaged in the low single digits annually, consistent with management’s stated cap below 2.5% going forward.

Before stepping into the forward math, it helps to look at how stock-based compensation has moved with revenue.

The level of dilution remains manageable, but it is persistent. Persistent dilution compounds over time in the same way revenue does.

For 2026, management has guided to roughly $590M to $620M in SBC expense. That level of compensation is structural to the model. Nearly every high-growth technology platform uses stock-based compensation. The discipline test centers on whether operating leverage compresses SBC as a percentage of revenue over time, allowing per-share owner’s earnings to scale meaningfully.

This is where many analyses stop. SBC gets labeled “non-cash,” adjusted metrics get highlighted, and dilution gets waved through. Inside F.L.O.W., I treat SBC as a real economic transfer because you cannot eat “adjusted” earnings. In SaaS businesses, stock-based compensation is often a structural part of employee pay, not simply a management choice. Engineers, sales teams, and operators expect equity participation. That reality does not eliminate the cost. SBC may not be cash leaving the building immediately, but if the share count is a slow-motion leak in the bucket, revenue growth alone will not protect per-share outcomes. Equity is ownership. Ownership dilution is permanent.

Management’s long-term target model projects $6B in revenue by 2028 and adjusted EBITDA margins around 28%. Free cash flow conversion is targeted around 60% of EBITDA. Dilution is committed to stay below 2.5% annually.

Those targets, if achieved, would demonstrate operating leverage. Targets alone, however, do not determine shareholder outcomes. The gap between adjusted EBITDA and what ultimately lands in a shareholder’s pocket is the gauntlet Axon has to run. That is where the math either confirms the narrative or contradicts it. Capital allocation behavior over the past several years adds another layer to that analysis.

Over the past several years, goodwill has expanded meaningfully due to acquisitions. Debt has been issued and repaid. Equity has been issued in size, including more than $2B in share issuance in 2025. Buybacks have occurred but have not offset issuance entirely.

Equity issuance at elevated valuations can be intelligent capital allocation if the proceeds fund high-return growth or de-risk the balance sheet. It can also quietly dilute long-term owners if incremental returns on deployed capital do not exceed the cost of that equity.

The balance sheet remains stable. Liquidity is strong and debt levels are manageable. The capital structure relies primarily on equity to fund growth, alongside improving operating leverage. Valuation now becomes the critical variable in determining per-share outcomes.

Axon is a high-quality, structurally durable business with strong growth and deepening ecosystem integration. Valuation today assumes continued growth and sustained excellence at scale. The critical variable is how effectively enterprise growth converts into durable per-share compounding at current price levels.

That is where the math becomes clearer.

Axon Owner’s Earnings, SBC, and Dilution Analysis

For Axon to sit inside the Opportunity tier of F.L.O.W., the analysis must distinguish between enterprise growth and per-share compounding.

Revenue growth has been obvious. Margin expansion is visible. Retention is strong. Revenue alone, however, does not accrue to shareholders. Owner’s earnings per share determine whether value compounds at the individual ownership level.

The starting point is a clean baseline.

1. 2025: What Did Owners Actually Earn?

2025 Operating Cash Flow: approximately $211M
2025 Capital Expenditures: approximately $136M

Reported Free Cash Flow:

211 – 136 = $75M

Now incorporate stock-based compensation.

2025 SBC expense: approximately $634M

If SBC is treated as a real economic cost, owner’s earnings for 2025 becomes:

$75M – $634M = negative $559M

That result reflects a business still operating in aggressive incentive expansion mode. Many investors exclude SBC because it is non-cash in the current period. Compensation paid in shares, however, transfers ownership over time and affects per-share economics directly.

2025 reflects a scale-build phase rather than a mature owner’s earnings profile. The path forward depends on whether operating leverage improves meaningfully from here.

2. 2026: Does Leverage Start Showing?

Management has guided for:

Revenue growth: 27% to 30%
Adjusted EBITDA margin: ~25.5%
SBC: $590M to $620M

Using midpoint assumptions:

2025 revenue: $2.78B
Assume 28% growth.

2026 revenue:

2.78 × 1.28 = $3.56B

EBITDA at 25.5%:

3.56 × 25.5% ≈ $908M

Free cash flow conversion target: ~60% of EBITDA.

908 × 60% ≈ $545M

Now subtract SBC.

Assume midpoint SBC: $605M

Owner’s earnings 2026:

545 – 605 = negative $60M

That represents a transition point in per-share economics.

At nearly $3.6B in revenue and mid-20% EBITDA margins, owner’s earnings are still approximately breakeven when SBC is treated fully.

This should tell you two things:

1. The business is scaling rapidly.

2. Incentive compensation remains a meaningful structural cost.

The path to real compounding depends on SBC declining as a percentage of revenue while operating leverage expands.

3. 2028: Translating the Target Model

Management’s 2028 targets:

Revenue: $6B
Adjusted EBITDA margin: 28%
Free cash flow conversion: ~60%

Translate those into dollars.

EBITDA:

6.0 × 28% = $1.68B

Free cash flow:

1.68 × 60% = $1.01B

Now the critical variable: SBC.

I’ll model two scenarios.

Scenario A: SBC at 12% of revenue

6.0 × 12% = $720M

Owner’s earnings:

1.01B – 720M = $290M

Scenario B: SBC at 8% of revenue

6.0 × 8% = $480M

Owner’s earnings:

1.01B – 480M = $530M

That range, $290M to $530M, represents realistic 2028 owner’s earnings under disciplined assumptions.

Now convert to per-share.

4. Dilution Modeling

Current diluted shares: ~78.9M

Assume dilution remains capped at 2.5% annually through 2028.

Year 1: 78.9 × 1.025 = 80.9
Year 2: 80.9 × 1.025 = 82.9
Year 3: 82.9 × 1.025 ≈ 85.0M

Projected 2028 share count ≈ 85M

Now per-share owner’s earnings:

Scenario A:
290 ÷ 85 ≈ $3.40

Scenario B:
530 ÷ 85 ≈ $6.20

So by 2028, under reasonable leverage and disciplined dilution, owner’s earnings per share likely fall between $3 and $6.

That is a significant improvement from breakeven today. But it is not explosive relative to a $550 stock price.

5. Extending to a Mature State

Now let’s forward beyond 2028 to see what mature economics look like.

Assumptions:

Revenue growth slows gradually from high-20s to mid-teens.
Long-term EBITDA margin stabilizes near 30%.
FCF conversion remains near 60%.
SBC compresses to 8% of revenue.
Dilution moderates to ~2% annually post-2028.

By 2035, under disciplined but optimistic assumptions, revenue might plausibly reach ~$12B to $13B.

At 30% EBITDA margin:

12.8 × 30% = $3.84B EBITDA

Free cash flow at 60%:

3.84 × 60% = $2.30B

SBC at 8%:

12.8 × 8% = $1.02B

Owner’s earnings:

2.30 – 1.02 = $1.28B

Projected shares by 2035:

Approximately 97M

Owner’s earnings per share:

1.28B ÷ 97M ≈ $13

That is a realistic long-term per-share outcome under strong execution. Thirteen dollars.

Now compare that to $550.

This is where valuation tension becomes visible.

6. Axon Revenue Growth vs Per-Share Economics

From 2025 to 2035 in this model:

Revenue grows roughly 4×.
Owner’s earnings per share grow from negative to $13.

Enterprise growth is powerful.
Per-share compounding is steady, not explosive.

This is not a criticism of Axon. It is simply the math of scaling a $40B company.

When businesses reach this stage, the difference between 20% revenue growth and 20% per-share intrinsic value growth becomes meaningful. Dilution, SBC, and margin ceilings begin to matter more than top-line acceleration.

The business is moving from early hypergrowth toward structured scaling.

At $550, forward returns depend on how much additional per-share economics can expand from here.

The focus shifts from projecting growth to defining what the valuation requires.

Axon Valuation at ~$550: What the Math Requires

With the structure defined and owner’s earnings normalized, valuation becomes arithmetic. At approximately $550 per share and roughly 79 million shares outstanding, Axon carries a market capitalization around $43 billion. That valuation reflects dominant-platform expectations.

A 10 percent annual return over the next decade requires $550 to compound to roughly $1,425, since 550 × 2.59 ≈ 1,425. By 2035, the stock would therefore need to trade near $1,425 per share to produce that outcome. Assume that by 2035 Axon operates as a mature but still growing infrastructure company and trades at 25 times owner’s earnings, a multiple that assumes durability and continued growth at scale. Under that framework, Axon would need to generate approximately $57 per share in true owner’s earnings by 2035 to support a 10 percent annual return from $550.

Under the disciplined projection outlined earlier, revenue scales into the low-teens billions, EBITDA margins approach 30 percent, free cash flow conversion remains near 60 percent, SBC compresses but remains meaningful, and dilution moderates but persists. Those assumptions produce approximately $13 per share in owner’s earnings by 2035. Thirteen versus fifty-seven creates a wide gap, and the current price embeds expectations materially above the conservative projection.

Applying inversion clarifies the requirement. If owner’s earnings must reach $57 per share and shares outstanding approach roughly 97 million by 2035, total owner’s earnings would need to approximate $5.5 billion annually. Translating that requirement into revenue under reasonable mature-state assumptions — 30 percent EBITDA margins, 60 percent free cash flow conversion, and SBC equal to 8 percent of revenue — produces a net owner’s earnings margin near 10 percent. At that margin, generating $5.5 billion in owner’s earnings would require approximately $55 billion in annual revenue.

Current revenue is $2.8 billion and the 2028 target is $6 billion. Reaching $55 billion by 2035 would require sustained growth near 30 percent annually for a decade at materially larger scale. That path represents an ambitious execution profile.

Assume exceptional execution: EBITDA margins expand to 35 percent, free cash flow conversion reaches 70 percent, and SBC declines to 5 percent of revenue. Under those assumptions, 35% multiplied by 70% produces a 24.5 percent pre-SBC cash margin. After subtracting 5 percent for SBC, the resulting net owner’s earnings margin approaches 19.5 percent. At that level of profitability, generating $5.5 billion in owner’s earnings would require roughly $28 billion in annual revenue, still nearly five times the 2028 revenue target.

This defines the valuation tension. Axon has historically grown revenue at 20 to 30 percent annually, and that track record is real. Expanding from $800 million to $1.6 billion represents one phase of growth. Expanding from $6 billion to $12 billion, and then from $12 billion toward $25 billion and beyond, represents another. Scale alters the difficulty curve.

Under the disciplined projection, owner’s earnings per share reach approximately $13 by 2035. Applying a 25 multiple would imply a valuation near $325 per share. Even at a 35 multiple, the implied value approaches $455. Both outcomes sit below $550. Breaking even over ten years at a 25 multiple would require approximately $22 per share in owner’s earnings, roughly 70 percent above the disciplined projection.

The analysis centers on expectations rather than business quality. The business remains strong, with high retention, meaningful backlog, improving software mix, and visible operating leverage. At $550, the valuation assumes continued scaling well beyond the 2028 trajectory, expanding margins, and declining SBC as a percentage of revenue. That path remains achievable, though it allows less margin for execution variability.

Inside F.L.O.W., this is what tight math represents. Enterprise growth can continue at attractive rates. Per-share returns depend on that growth exceeding the assumptions embedded in the multiple. At this level, valuation contributes materially to the forward outcome, and execution must extend beyond the baseline path.

Owning a strong company differs from owning a strong investment at a given price. Price defines discipline.

Where AXON Stock Fits Inside the F.L.O.W. Framework

After stepping through the business model, incentive structure, owner’s earnings normalization, and reverse DCF, Axon settles into a defined position within F.L.O.W.

The company is structurally strong and priced for sustained excellence. Inside F.L.O.W., that positioning carries implications for capital allocation.

Axon does not present the characteristics of a Front-Load opportunity. The balance sheet shows no stress, no temporary impairment, and no forced selling dynamic creating asymmetric entry. Ownership is broad, institutional coverage is deep, and the company is consistently regarded as a best-in-class compounder.

The capital structure does not rely on financial engineering. Debt levels remain manageable, liquidity is healthy, and the balance sheet supports continued growth.

Axon aligns most closely with the Opportunity tier: high quality, durable economics, expanding margins, recurring revenue, and consistent execution. Opportunity tier positioning also implies price sensitivity. Market recognition of quality shifts the focus toward forward return potential rather than discovery.

Revenue growth in the 20 to 30 percent range has been sustained for years. The backlog remains substantial. Retention levels are elevated. The ecosystem continues to deepen.

Scale now defines the next phase. Expanding from hundreds of millions to low billions represents one stage of growth. Expanding from six billion toward twelve billion and beyond introduces different operational demands. International expansion adds complexity. Procurement cycles carry greater weight. Competitive responses intensify.

The business retains the capacity to scale further. Per-share economics must expand at a rate that supports the expectations embedded in the current multiple.

The prior modeling indicates that double-digit returns from $550 require a combination of outcomes: revenue growth exceeding the 2028 trajectory for an extended period, operating margins expanding meaningfully beyond 28 percent, and stock-based compensation compressing as a percentage of revenue to allow owner’s earnings per share to accelerate.

Simultaneous progress across those dimensions supports the valuation. Performance that merely tracks existing targets compresses forward return potential.

The analysis centers on discipline rather than pessimism. Axon remains one of the stronger structural businesses in public safety technology, with durable recurring revenue, visible operating leverage, and clear long-term targets.

F.L.O.W. separates admiration of the enterprise from assessment of the entry price. At lower price levels, margin of safety expands and enterprise strength translates more directly into per-share compounding. At $550, the underwriting case assumes sustained dominance and continued operational outperformance.

Position sizing reflects that reality. Axon fits as a high-quality Opportunity tier compounder that rewards patience in entry and disciplined capital allocation. The business remains strong. The valuation embeds continued excellence.

That defines where Axon sits today.

Inside F.L.O.W., position sizing follows from that assessment, and discipline in sizing protects long-term compounding. At $550, that discipline argues for restraint rather than urgency.

The same philosophy guides my training in the dojo as I work toward a second-degree black belt. If this deep dive added value, you can support the work with a coffee.

Keep Moving,
TuDi

Subscribe now

Disclaimer

The information in this article is provided for informational and educational purposes only.

The information is not intended to be and does not constitute financial advice or any other advice, is general in nature, and is not specific to you. Before using this article’s information to make an investment decision, you should seek the advice of a qualified and registered securities professional and undertake your own due diligence.

None of the information in this article is intended as investment advice, as an offer or solicitation of an offer to buy or sell, or as a recommendation, endorsement, or sponsorship of any security, company, or fund. The author is not responsible for any investment decision made by you. You are responsible for your own investment research and investment decisions.

Management didn’t just beat earnings. They reinforced long-term growth targets. The market responded by repricing those expectations aggressively. But $6 billion of new assets didn’t physically appear overnight. Discipline requires separating narrative acceleration from economic reality. The only thing that matters is whether time is still working for capital at $520 the way it was at $442.

Axon’s Structural Shift: From Devices to Recurring Infrastructure

Axon is no longer a device manufacturer. It has become an embedded infrastructure layer for public safety. The model begins with hardware, TASERs and body cameras, and ends with software integrated into departmental workflows. Once digital evidence lives inside Axon’s cloud, switching costs rise materially. The shift from one-time product sales to recurring subscriptions changes the economic profile of the business and increases lifetime value.

Stock-Based Compensation and Per-Share Economics

The structural case is real, but it is not frictionless. Stock-based compensation remains significant, exceeding $600M in 2025. Founder Patrick Smith’s long-term orientation is an advantage, but aggressive use of equity means growth must translate into per-share economics, not just revenue expansion. At roughly a $40B valuation, sustained high-20% revenue growth and expanding margins are no longer upside. They are embedded expectations.

Axon at $520: What Growth Must Be True

The move to $520 does not invalidate the bull case. It raises the bar. At this price, the narrative remains strong, but the math becomes more demanding. Execution risk did not disappear. It became more expensive.

Later this week, I’ll publish the full structural deep dive. Not just a valuation model, but the entire operating machine.

I’ll dig into the business economics, management incentives, stock-based compensation discipline, capital allocation, per-share compounding, and then run the reverse DCF to quantify what growth is embedded in $520. I’ll identify what has to go right over the next five to ten years for a 10% annual return to materialize, and where the breakpoints sit if execution slips.

If you want the numbers and the structure behind the narrative, subscribe below.

Subscribe now

Disclaimer

The information in this article is provided for informational and educational purposes only.

The information is not intended to be and does not constitute financial advice or any other advice, is general in nature, and is not specific to you. Before using this article’s information to make an investment decision, you should seek the advice of a qualified and registered securities professional and undertake your own due diligence.

None of the information in this article is intended as investment advice, as an offer or solicitation of an offer to buy or sell, or as a recommendation, endorsement, or sponsorship of any security, company, or fund. The author is not responsible for any investment decision made by you. You are responsible for your own investment research and investment decisions.

Update: With the price at $380.55, the divergence from trailing Free Cash Flow of $6B+ has reached a 10-year extreme.

Intuit has fallen nearly 45% from its 52-week highs, currently trading at $380.55. The explanation seems simple. Artificial intelligence is compressing software multiples. Agents are replacing interfaces. SaaS is being repriced across the board.

But broad narratives often flatten important distinctions.

Intuit today generates roughly 19 billion in annual revenue. Free cash flow exceeds 6 billion. This isn’t just recent momentum, it is a decade of consistency. Over the last ten years, Intuit has maintained a 16% revenue CAGR while Free Cash Flow has compounded at an even more impressive 18% CAGR. This ‘operating leverage gap,’ where cash flow outpaces revenue growth, is the hallmark of a scaling platform, not a fragile software tool.

That does not describe a fragile business. The concern is not what Intuit has done, but whether it remains structurally essential in an AI-driven world.

Intuit is not a horizontal collaboration tool or a discretionary SaaS add-on. It sits in the movement, recording, and compliance of money; payroll tax remittance, merchant processing, invoicing, bookkeeping, tax filing, credit modeling. These are regulated workflows. Errors carry penalties. Replacing those layers is fundamentally different from replacing a UI.

Global Business Solutions now accounts for more than 11 billion of revenue. QuickBooks is embedded inside millions of small businesses. Not just as bookkeeping software, but as the operating system for payroll, payments, and financial reporting.

The Consumer segment contributes nearly 8 billion of revenue. TurboTax remains the dominant digital tax filing platform. Credit Karma extends Intuit’s presence beyond tax season into year-round financial behavior.

CEO Sasan Goodarzi has reframed the company repeatedly over the last several years as an “AI-driven expert platform.” The emphasis is not on tools. It is on automation. The shift from “do it yourself” to “done for you” is deliberate. AI is not being bolted on to defend pricing. It is being embedded to automate outcomes.

The stock, however, is being repriced as though structural fragility has emerged. There are legitimate risks, but they are not equal in probability, magnitude, or time horizon.

• The most meaningful structural risk is government-sponsored tax filing expansion. TurboTax generates roughly five billion dollars in annual revenue. A broad, technically robust public alternative capable of handling complex returns would impair that base. But such an outcome requires sustained political alignment, product expansion beyond simple returns, and mass adoption. Recent policy reversals suggest the probability weight has declined. It remains real, but it is political, slow-moving, and reversible.

• The second category of risk is AI-driven pricing compression. If artificial intelligence commoditizes entry-level bookkeeping, lower-tier subscription pricing could compress. That risk is moderate and gradual rather than sudden. It must also be weighed against AI’s ability to increase automation, attach rates, and monetization through “done-for-you” services. AI is as likely to reallocate revenue mix as it is to eliminate it. The net impact depends on execution.

• Credit Karma introduces cyclical sensitivity rather than structural impairment. Lending markets influence conversion rates and referral economics. During tighter credit cycles, revenue moderates. During expansionary cycles, it accelerates. This creates volatility, not obsolescence. The long-term asset is the data layer, not short-term loan origination volume.

• Low-end accounting competition is ongoing and real. Micro-businesses are price-sensitive and alternatives exist. However, Intuit’s economic engine is increasingly driven by payments, payroll, financing, and mid-market expansion rather than entry-level bookkeeping. Competitive pressure at the bottom tier may limit ARPU expansion but is unlikely to dismantle ecosystem economics.

• Compute cost inflation from AI deployment is the least structural risk. Higher inference costs may compress gross margin modestly. Even a 100 to 200 basis point operating margin impact does not break a business generating mid-twenties operating margins and strong incremental leverage. This is a margin management issue, not a business model threat.

The true underwriting variable is not any single headline risk. It is whether the institutionalized system of innovation I saw during my four years at the company, specifically the Design for Delight (D4D) and ‘Follow-me-home’ disciplines, not to mention the culture and management decisions, is enough to maintain low-teens owner’s earnings growth over the next decade.

The market is stuck on the ‘AI Story,’ but having been inside during the cloud transition, I know the real debate is about institutionalized durability. If that durability is real, $380 represents compression, not impairment.

To determine if that durability is real, I have moved past the narrative to the specific ‘underwriting’ math required to own this at a 52-week low:

• The Adjusted FCF: Why the 10% SBC “step-up” changes the terminal value of this stock.

• The Hurdle Rate: The exact revenue growth Intuit needs to hit to deliver a 12% IRR from today’s $380.55 base.

• The Scenario Matrix: My bull/bear price targets through 2030 based on owner’s earnings.

[Unlock the Full Underwriting Model to see the math and the cultural ‘operating system’ behind the thesis]

Read more

In the previous Trading vs. Compounding post published on Monday, I defined trading and compounding as two distinct modes, each with its own expectations and failure modes. This follow-up looks at what happens in the space between them, when a stock sits at the boundary, and investors don’t realize the underlying behavior has changed.

The goal here isn’t to decide whether a stock is good or bad. It’s to decide what role it can reasonably play in a portfolio right now.

The most common investing mistake: misclassifying a stock’s role

Most investors label stocks by reputation. If a company is dominant and financially strong, it gets mentally filed away as a compounder. That label often sticks even after the business itself starts behaving differently.

Compounding isn’t a personality trait; it’s an observable pattern. It shows up in how cash is generated, how much is reinvested, and how predictable the payoff is over time. When those patterns change, expectations need to change with them.

This is where confusion sets in. A stock can remain a great business while no longer functioning as a clean compounder. It may still reward traders while frustrating long-term holders. None of that requires deterioration. It only requires transition.

Why Meta is a useful example for classifying a stock’s role

Meta is a useful example precisely because so many people think they understand it. It’s large, profitable, deeply embedded in daily life, and constantly discussed across social media and investing circles. At the same time, it has entered one of the most aggressive reinvestment cycles of any large public company.

That combination creates a mismatch. Investors bring compounder expectations into a business that is deliberately choosing uncertainty in pursuit of future advantage. That choice may turn out to be brilliant. It may also take longer to pay off than many holders expect. The key point is that the behavior of the business has shifted, even if the quality has not.

This is not a buy or sell discussion. It’s a classification exercise.

Applying the lens: how business behavior changes investor outcomes

When a business prioritizes heavy reinvestment, the financial picture gets messier. Free cash flow becomes noisier. Margins stop expanding or actively compress. Earnings quality becomes harder to judge because today’s results are being intentionally sacrificed for tomorrow’s capacity.

None of that breaks the business. But it does break the clean compounding profile investors often anchor to. Compounding, in its simplest form, relies on a stable conversion of revenue into owner earnings. When that conversion becomes an open question, the investment shifts from compounding toward underwriting.

Underwriting is not a flaw, it’s a different activity. It asks different questions and demands a different kind of patience. The problem is that most investors don’t consciously switch modes. They continue holding the stock as if its behavior hadn’t changed, then feel surprised when the experience no longer matches their expectations.

Why price action feels so unsatisfying here

This is where both traders and long-term holders get uncomfortable. Traders struggle because the narrative is long-dated and volatile, making short-term moves harder to trust. Long-term holders struggle because returns feel delayed and uneven, even as business headlines remain strong.

That tension fuels endless debate about valuation and “fair value,” when the underlying issue is simpler: the stock is being asked to do something different than it did before. The payoff, if it comes, is back-loaded. Anyone expecting near-term validation is likely to feel stuck.

In training terms, stance and movement are misaligned. Power leaks not because the technique is wrong, but because the body isn’t organized for what it’s trying to do.

Re-classifying expectations when a stock changes behavior

In situations like this, the most useful question isn’t whether the business will succeed. It’s whether the investor is being paid to wait while that success is being built.

If the answer is unclear, the position may still make sense, but expectations need to change. That might mean treating it as a transition state rather than a core compounder. It might mean resizing the position or pairing it with more stable assets that help absorb the volatility.

The goal is to stop the bleed of mental energy. A position should be a deliberate choice, not a source of constant second-guessing driven by a mislabeled role.

How this fits into the F.L.O.W. framework

F.L.O.W. Investing isn’t about finding a single holding period that works for every stock. It’s about moving capital through different roles deliberately. Some capital is deployed tactically, with clear targets and defined timeframes. Some stays longer, backing growth before profitability is fully proven. Some is parked in durable compounders or broad vehicles designed to do one thing well, quietly, over long stretches of time.

The mistake is trying to force every position into the same bucket. That’s how good trades overstay their welcome, and good businesses turn into bad experiences.

Deep-dive analyses, owner’s earnings models, and margin of safety work still matter. But they come after classification, not before. If the role isn’t clear, the math won’t save you.

The right question investors should ask

Instead of asking whether a stock is expensive or cheap, try asking this:

Am I being paid to wait, or am I underwriting a transition?

That question doesn’t guarantee better outcomes. But it dramatically reduces self-inflicted mistakes. Over time, that discipline matters more than any single idea.

Keep Moving,

TuDi

Disclaimer

The information in this article is provided for informational and educational purposes only.

The information is not intended to be and does not constitute financial advice or any other advice, is general in nature, and is not specific to you. Before using this article’s information to make an investment decision, you should seek the advice of a qualified and registered securities professional and undertake your own due diligence.

None of the information in this article is intended as investment advice, as an offer or solicitation of an offer to buy or sell, or as a recommendation, endorsement, or sponsorship of any security, company, or fund. The author is not responsible for any investment decision made by you. You are responsible for your own investment research and investment decisions.

When frustration builds, it usually gets directed at the stock. It was overhyped. The thesis changed. The market turned irrational. Sometimes that explanation holds. More often, the issue isn’t the idea or even the entry, it’s that the position is being managed under a different set of assumptions than the ones it was bought under. Losses and disappointment tend to come from playing the wrong game after the position is already on.

That distinction matters because trading and compounding aren’t preferences or investing “styles.” They are structurally different activities with different sources of return, different risk profiles, and different ways of defining success. If those differences aren’t made explicit early, the market has a habit of forcing the lesson later, usually at a point when adjusting course is more costly than it needed to be.

Why this matters more than stock picking

Many investing problems don’t originate with the initial decision. They show up later, when the reason for owning something quietly changes but the position itself doesn’t.

The choice between trading and compounding needs to be made before a security is selected, because that choice determines how time is treated, how volatility is interpreted, and what actually counts as being wrong. Without that clarity, even a strong business or a well-timed idea can turn into a frustrating experience. Risk isn’t just drawdowns or red numbers on a screen, it’s the gap between how a position is supposed to work and how it’s actually being managed. Before talking about specific businesses or prices, those rules need to be explicit.

What a trade really is

A trade gets paid by timing. Returns come from catalysts, shifts in sentiment, positioning, or narrative changes. A trade can be based on real information or solid insight, but the payoff depends on price moving before the opportunity fades.

There’s nothing unserious about that. Well-run trades can be disciplined and profitable, and in volatile markets they’re often an efficient way to build early capital. But trades have rules, and ignoring them is where problems begin. Trades fail when exits aren’t defined, when position size quietly assumes permanence, or when a short-term idea is forced to justify long-term ownership. A trade doesn’t fail because the story breaks, it fails when the story changes and the exit is avoided. Time isn’t neutral here. If nothing happens, risk increases while value doesn’t.

In the next piece on Tuesday morning ET, February 10, I’ll apply this framework to a real, widely followed stock. Not to argue for a buy or sell, but to show how misclassifying a role creates frustration even when the business itself is strong.

Keep Moving,

TuDi

From a strategic or policy perspective, that framing is easy to understand. From an investment perspective, it deserves more scrutiny. The strategic importance of a technology is not the same thing as its ability to compound capital. Those two ideas often move together early on, and then separate once the economics start to matter. SMRs sit squarely at that intersection today.

This isn’t theoretical. Investor excitement around SMRs has ramped up over the past year, with stocks like NuScale and Oklo reacting quickly to big energy announcements and policy tailwinds. The market is pricing the future, even though the underlying projects are still consuming capital today.

This piece steps back from that excitement to ask a simpler, harder question: what would actually have to be true for SMRs to become durable compounding businesses rather than perpetual capital projects?

What “small” and “modular actually mean in practice

SMRs are designed to address some of the problems that have historically plagued nuclear power. Smaller reactor sizes are meant to reduce upfront capital requirements. Modular construction is intended to standardize components, shorten build times, and improve cost predictability through repetition rather than customization.

That promise matters because nuclear’s long-standing investment problem has never been demand. It has been cost overruns, regulatory delays, and capital intensity that push returns far into the future while concentrating risk in the present. SMRs are marketed as a way to compress that timeline and spread that risk.

What often gets missed is that smaller doesn’t mean cheap, and modular doesn’t mean self-funding. Cash comes much later. The efficiencies only show up after repetition, and repetition takes time and money, much like how in martial arts, form only becomes functional after years of disciplined practice, not after the first demonstration. That gap is where most investor narratives begin to weaken.

The cash-flow bridge most SMR narratives skip

SMRs are front-loaded by nature. Capital goes out long before it ever has a chance to come back. Development, licensing, site preparation, and construction all require funding well ahead of operation. During that period, companies rely on external capital, equity dilution, government backing, or strategic partners.

This creates a familiar but uncomfortable dynamic. Optimism tends to price in a future state where reactors deploy smoothly and returns normalize. The years of capital consumption in between are treated as a bridge rather than a risk. But for compounding, that bridge matters more than the destination.

Bruce Lee emphasized absorption over resistance, the idea that meeting force head-on often transfers the damage rather than neutralizing it. The parallel here is uncomfortable but clear: Capital-intensive businesses don’t eliminate risk, they redirect it. If a company can’t absorb the force of its own burn rate through operations, that pressure shows up directly at the shareholder level, usually through dilution. Until a model can fund its own growth, the pressure doesn’t disappear, it’s simply absorbed by the investors who are supplying the capital while the economics try to catch up.

This is the bridge investors have to cross. Most of the excitement is focused on the destination, but the structural damage often happens during the crossing.

One way to visualize this gap is to map where capital flows over time:

NuScale as an SMR case study

NuScale has become one of the most visible public-market expressions of SMR enthusiasm. That makes it a useful case study, less because it defines the category and more because it shows how much capital these projects tend to pull forward.

NuScale isn’t the villain here. It’s simply the clearest example of how large-scale infrastructure pulls cash forward while pushing returns out. Years of development and regulatory engagement preceded any realistic prospect of revenue. Along the way, funding came from public markets, government support, and strategic relationships, all sources that share one common trait: they are not internally generated cash flows.

That distinction matters because it changes behavior. When growth depends on outside capital, the priority quietly shifts toward keeping confidence intact and momentum alive. Delays or design changes stop being just engineering problems. They start to matter because they influence perception, funding, and who’s still willing to write the next check. Over time, managing expectations can become just as important as building the thing itself.

This isn’t unique to NuScale, and it doesn’t suggest poor execution or bad intentions. It’s simply what happens when complex, regulated infrastructure meets public markets. The risk for investors is mistaking visibility and access to capital for evidence of compounding economics. In many cases, it just means the development risk has been passed along, not eliminated.

The broader SMR investment picture

NuScale isn’t alone. Companies like Oklo have also drawn investor attention, often on the promise of faster timelines or more advanced designs. The technology differs, but the underlying capital questions tend to look very similar.

Across the space, most of the excitement is aimed at the end state, a future where reactors are deployed smoothly and energy output produces steady returns. Much less attention is paid to the years in between, when uncertainty is highest and capital is most exposed. From an investment standpoint, those years aren’t a detail. They’re the hinge everything turns on.

When multiple companies are valued on future promise before durable economics are visible, public markets start acting as risk capital. That doesn’t make the opportunity invalid, but it does change the nature of the bet in a meaningful way.

Why compounding is hard in capital-intensive models

Compounding tends to work best when a business can take the cash it already generates and reinvest it at attractive rates, on its own timeline and at its own pace. Capital-intensive models flip that around. The big investments have to be made upfront, long before there’s much flexibility, and any real optionality only shows up much later, if it shows up at all.

In my experience, infrastructure returns tend to be project-specific rather than systemic. One successful build doesn’t automatically translate into a repeatable, high-return model. Regulations vary, financing changes, and cost curves don’t bend quickly. Even when things go right, the next phase often needs fresh capital, sometimes on worse terms. That doesn’t mean good outcomes are impossible, but it does make long-term compounding a lot harder.

What would have to be true for SMRs to compound

For SMRs to jump the gap from compelling technology to a compounding business, a lot of things have to go right at the same time. We don’t just need lower costs, we need a predictable playbook where one project looks exactly like the next. No more bespoke engineering. No more shifting regulatory goalposts. Most importantly, those first few reactors have to actually spit out enough cash to fund the next ones. If you're constantly diluting shareholders to keep the lights on, you aren't compounding, you're just surviving. This isn't a knock on the tech, it's just a reality check on how hard it is to build a money-making machine out of concrete and steel.

Bringing it back to capital discipline for investors

Periods of enthusiasm often blur the line between strategic importance and investment quality. SMRs may matter enormously to the global energy mix, but that doesn’t guarantee that early public-market vehicles will compound capital for you.

Capital discipline is about structure, not stories. It’s the math that asks:

• Who is actually footing the bill for growth?
• When does the cash finally show up?
• What happens to your stake when timelines inevitably stretch?

In emerging, capital-intensive industries, these questions are usually answered slowly, and often at the expense of the first wave of investors.

The world might need SMRs to work. But as an investor, you still have to ask: Are you comfortable being the one who pays for the world’s lessons?

Keep moving,

TuDi

Subscribe now

Disclaimer

The information in this article is provided for informational and educational purposes only.

The information is not intended to be and does not constitute financial advice or any other advice, is general in nature, and is not specific to you. Before using this article’s information to make an investment decision, you should seek the advice of a qualified and registered securities professional and undertake your own due diligence.

None of the information in this article is intended as investment advice, as an offer or solicitation of an offer to buy or sell, or as a recommendation, endorsement, or sponsorship of any security, company, or fund. The author is not responsible for any investment decision made by you. You are responsible for your own investment research and investment decisions.